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Abstract 
 The model selenate respiring bacterium Thauera selenatis produces 
selenium deposits on a nano-scale during selenate respiration. Selenium 
deposits have been isolated from Thauera selenatis growth medium, analysed 
and found to be red solid particles with a diameter of approximately 130 nm. 
Analysis of the growth medium has suggested that selenium deposits are 
exported out of the cell, in a process that is facilitated by a key protein termed 
the selenium export factor, SefA. This protein has been expressed in 
Escherichia coli and the two recombinant His-tagged forms (His-SefA and 
His-SefA-His) have been purified. It has been suggested that proteins may 
influence selenium nanoparticle assembly. Debieux and co-workers 
investigated the size of selenium nanospheres produced in vitro in the 
presence of His-SefA and found that they were approximately 300 nm in 
diameter. This is significantly different to those produced during the growth of 
Thauera selenatis, and so the effect of His-tagging the SefA protein on the 
selenium nanoparticles produced was investigated.  
 A non-His-tagged construct of the SefA protein, rSefA, was produced 
by proteolytic cleavage of the N-terminal His-tag from His-SefA using 
thrombin. This resulting protein with no His-tags was expected to produce 
selenium nanospheres most similar to those produced in Thauera selenatis 
during selenate respiration. Nanoparticles of approximately 130 nm in size, 
similar to those produced in the bacterium, were produced in the presence of 
10 µg/ml rSefA. The size of the nanoparticles was determined using 
Nanoparticle Tracking Analysis in collaboration with NanoSight Ltd. Selenium 
nanospheres produced in the presence of His-SefA showed a decrease in 
particle size as the protein concentration increased. By contrast, those 
produced in the presence of rSefA showed an increase in particle size as the 
protein concentration increased. In the presence of His-SefA-His changing the 
protein concentration had no effect on the size of the selenium particles 
produced.  
 !
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Abbreviations 
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1 Introduction 
1.1 An introduction to nanoparticles 
 The Encyclopaedia of Nanoscience and Nanotechnology defines a 
nanoparticle as a solid colloidal particle, which can range from 1 – 1000 nm in 
size (Soon-bark et al., 2004). The colloidal particles consist of 
macromolecular materials that may include an active principle. This active 
principle may be encapsulated or dissolved in the suspension, or alternatively 
directly adsorbed or attached to particles (Kreuter, 2004).  This active 
principle can be a biologically active material or a drug, and encapsulating or 
attaching such materials onto nanoparticles can make it possible to target 
organs which were previously inaccessible within the human body (Ehrenberg 
et al., 2009). Recently, a lot of research has focussed on the use of 
nanoparticle technologies in drug delivery, specifically to the central nervous 
system. A review by Kreuter that addresses how drugs are delivered to the 
brain highlights how the blood-brain barrier has so far proven to be a 
significant obstacle for drug delivery to tissues within the body (Kreuter, 
2013). Several previous studies, investigating the transport of drugs across 
the blood-brain barrier, found that the use of polymeric nanoparticles enables 
biological agents such as peptides and macromolecules to access cerebral 
tissues from the blood stream (Kurakhmaeva et al., 2009; Wohlfart et al., 
2012). Questions remain unanswered regarding the mechanism involved in 
the delivery of the drugs to such previously inaccessible places within the 
body, leading to recent research into nanoparticle-mediated drug transport, 
the influence of surface properties and/or targeting ligands (Kreuter, 2013). 
Consequently nanoscience is becoming increasingly important as an area of 
research. 
1.2 The functionalisation of nanoparticles by a protein corona 
 Nanomaterials have become increasingly popular in science due to 
their wide range of applications, both biological (Coppage et al., 2011) and 
technological (Yang et al., 2012). There has been extensive research into the 
biomedical uses of nanotechnology due to attractive properties that are 
enhanced at such a small scale. Nanoscale particles have distinctive 
! 11!
properties; optical, chemical and structural, which set them apart from larger 
molecules (Yang et al., 2012). One example being the high surface-to-volume 
ratio, which can enhance catalysis by further exposing the metallic active site 
(Coppage et al., 2011; Dell’orco et al., 2012). It has been found that 
interactions between the nanoparticle and their intended biological target, for 
example biological milieu, depend upon the structure of each individual 
nanoparticle (Prapainop et al., 2012). This structure is controlled by surface-
bound proteins and lipids. 
 In a biological environment, all nanoparticles may acquire a 
heterogeneous surface coating of biomolecules, such as protein and lipids, 
termed a protein corona (Prapainop et al., 2012). There is competition 
between proteins and other biomolecules to bind to the surface of the 
nanoparticles (Gebauer et al., 2012). There are many factors which influence 
how this corona is formed such as size, charge, stability of the nanoparticles 
and the properties of the proteins themselves (Del Pino et al., 2013). 
Nanoparticles have high surface free energy, causing molecules, particularly 
proteins, to adsorb onto their surfaces (Wolfram et al., 2014). Forces including 
Van der Waals interactions, hydrogen bonds, hydrophobic interactions and pi-
stacking interactions are responsible for the adsorption of protein molecules 
onto the surface of nanoparticles (Saptarshi et al., 2013; Wolfram et al., 
2014). Proteins can be adsorbed weakly or strongly onto the nanoparticle 
surface (Treuel et al., 2014) and form relative soft or hard coronas (Monopoli 
et al., 2011). Soft protein coronas form on shorter time scales and these then 
evolve into hard coronas over an incubation period of hours (Monopoli et al., 
2011; Gebauer et al., 2012). By contrast, a soft corona involves quick, 
reversible adsorption of proteins with fast exchange rates (Saptarshi et al., 
2013), whereas a hard corona is defined by the adsorption of proteins with 
relatively slower exchange rates (Monopoli et al., 2011). In bacterial 
microcompartments (Tanaka et al., 2008), large proteins are often folded into 
complex structures composed of non-covalent protein-protein interactions 
(Fletcher et al., 2013). These self-assembled cage-like particles could have 
useful applications in controlled delivery and release of drugs, sensing and in 
the preparation of protocells for synthetic biology (Uchida et al., 2007; 
Agapakis et al., 2012; Hammer et al., 2012). 
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 The protein corona is a major determinant for functionalisation of 
nanoparticles in vivo as it reflects their physical surface properties such as 
size and shape. Modification of these properties can control the interactive 
abilities of the nanoparticles and it is often necessary for highly hydrophilic 
molecules to coat the surface of the nanoparticles to prevent protein 
adsorption (Yang et al., 2012). This happens as the nanoparticles are coated 
with molecules specific to the proteins of the associated corona, enabling 
these molecules to target particular proteins and cause protein misfolding 
(Prapainop et al., 2012). Such misfolding can initiate access for the 
nanoparticles into cells which they may not be able to target otherwise via 
cell-specific uptake. Whilst the protein corona determines the function of the 
nanoparticles (Yang et al., 2012), the surface of the nanoparticles themselves 
can also have an effect on the structure of the adsorbed proteins and 
therefore affect the bio-reactivity of the nanoparticles (Saptarshi et al., 2013). 
It has been suggested that protein adsorption onto nanoparticle surfaces can 
be regarded as binding ligands to the nanoparticles (Del Pino et al., 2013). 
Like other ligands, proteins are able to displace other biomolecules as they 
adsorb and desorb onto the nanoparticle surface. Proteins are not very stable 
(Treuel et al., 2014) and so can form certain interactions with different 
nanoparticle surfaces which could affect the protein conformation (Gebauer et 
al., 2012). Structural changes may require a strong interaction, but could 
result in a loss in the biological function of the protein (Treuel et al., 2014). 
Such changes in protein conformation caused by adsorption of the proteins 
onto the particle surface could expose new antigenic sites (Lynch et al., 2006) 
and novel “cryptic” peptide epitopes, as found by Klein and co-workers (Klein 
et al., 2007). The exposure of such sites could result in an immune response 
(Brandes et al., 2006), which could ultimately promote autoimmune diseases 
if launched against a self-protein (Nel et al., 2009). 
 Being able to reach new areas of biological surroundings with 
nanoparticles in this way has generated much more research into the use of 
nanomaterials (Prapainop et al., 2012). It has also highlighted new uses of 
nanomaterials, for example surface attachment of polysaccharides to 
nanoparticles can increase the ability of the nanoparticle to permeate cells 
and therefore improve cancer targeting within the body (Yang et al., 2012). 
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Dell’orco et al. (2012) have investigated the advance in nanotechnology and 
how it has introduced new devices and procedures. These involve 
nanoparticles with unique physicochemical properties, which can target and 
reach parts of the body that have never been accessed before by 
nanomaterials. The authors of this paper examined computationally whether 
or not the nanomaterials are always successful in their targeting and delivery 
and how the protein corona would affect this (Dell’orco et al., 2012).   
 Nanomaterials and their associated protein coronas stabilise the 
delivery of drugs in vitro (Dell’orco et al., 2012; Dittrich et al., 2012). A study 
by Dittrich et al. has recently suggested that if nanoparticles were coated 
exclusively in peptides their physicochemical properties could be finely tuned 
corresponding to their delivery pathway (Dittrich et al., 2012). Interactions 
between peptides and protein coronas and how these stabilise nanoparticles 
are of particular interest. Peptides stabilise nanoparticles and allow physical 
properties such as size and shape to be controlled, it is the interaction 
between the nanoparticle and the peptide itself that is poorly understood 
(Coppage et al., 2011). 
1.3 Applications of Nanoparticles 
 Millington et al. have investigated how nanoparticles used in 
sunscreens are able to generate free radicals and reactive oxygen species 
upon their absorption of ultraviolet rays from the sunlight (Millington et al., 
2014). This in-turn can lead to ultraviolet radiation-mediated skin damage 
(Sander et al., 2002). These nano-sized particles could be modified by the 
attachment of ligands at the nanoparticle surface to reduce these adverse 
effects. There are many ways that one can be exposed to nanoparticles, 
including cosmetics and certain foods, however the main route is inhalation 
(Ehrenberg et al., 2009). Some nanoparticle activity occurs simultaneously 
with exposure, even via inhalation, however it has been shown that once 
inhaled the nanoparticles are able to enter the blood circulation (Nemmar et 
al., 2002; Ehrenberg et al., 2009). Dell’Orco et al. suggest that when 
nanoparticles are used for drug delivery or imaging, the nanoparticles are 
required to be injected either intravenously or directly to the target area 
(Dell’orco et al., 2012).  
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 Often nanoparticles follow different routes within the body before 
reaching their final target (Ehrenberg et al., 2009), recently research has 
focused on the interactions of proteins with nanoparticles and whether or not 
they affect their targeting ability (Almeida et al., 2007; Illum et al., 2007; Tan et 
al., 2010). Interactions on the surface of nanoparticles have a large effect on 
where the particle will stop, for example protein adsorption can determine 
where a particle will target and how it gets there (Ehrenberg et al., 2009). 
Ehrenberg et al. investigated how proteins interacted with polystyrene 
nanoparticles, and how these particles bound to endothelial cells cultured 
from human veins. The investigation found that the amount of protein 
adsorbed onto the nanoparticles was directly related to how they bound to the 
endothelial cells. They also found that non-specific interactions largely 
accounted for the interactions between the nanoparticles and the cells 
(Ehrenberg et al., 2009).  
 Nanoparticles can have a functional importance for delivering drugs 
and proteins themselves as they allow proteins and other larger molecules to 
adsorb onto their surface and pass through barriers and membranes into 
areas which they are too large to normally access. For example, in the 
respiratory tract of the human body, the mucosa form a complex barrier which 
macromolecules such as proteins are unable to filter through (Dombu et al., 
2013). Dombu et al. have explored different applications of nanoparticles such 
as cancer therapy, central nervous system targeting and vaccination (Dombu 
et al., 2012). Adsorbing proteins to nanoparticles can make them more 
accessible to various parts of the body therefore increasing their therapeutic 
potential (Dombu et al., 2012). However, once again targeting remains an 
issue with therapeutic peptides associated to nanoparticles, as this can 
reduce stability and activity. With vaccination, nanoparticles are able to bind to 
antigens and deliver them to the required site without degradation (Prieur et 
al., 1996). Coating the nanoparticles with antigens increase the uptake of the 
antigens into the cells and can provide immunisation against infections both 
airborne and blood-borne. Cancer cells over express protein markers, 
therefore have the potential for protein-protein interactions (Dombu et al., 
2013). Protein or peptide based drugs are often developed to target cancer 
cells as they can take advantage of these protein-protein interactions (Dombu 
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et al., 2013). Once again, nanoparticles are useful as the proteins themselves 
are too large to cross many barriers within the body. Specific protein coated 
nanoparticles have been developed to interact with the protein markers on 
particular cancerous tumors. Targeting the central nervous system to deliver 
therapeutic proteins to the brain involves transport through the nasal route. 
Associating the proteins with nanoparticles increases their bioavailability and 
targeting power. As with many modern applications of nanoparticles, the exact 
mechanisms of the protein transport to their target are unknown (Dombu et 
al., 2013). 
 The act of coating the nanoparticles with proteins is, as described 
previously, the formation of a protein corona. Dell’Orco et al. state that the 
protein corona assists with nanoparticles and their therapeutic uses (Hu et al., 
2011; Dell’Orco et al., 2012). The protein corona is able to lower the 
cytotoxicity of the nanoparticles, enabling them to be used in nanomedicine. 
There have been several investigations into the cytotoxicity of engineered 
nanoparticles, including silica (Chang et al., 2007), quantum dots (Derfus et 
al., 2004; Hoshino et al., 2004) and gold nanorods (Hauck et al., 2008), all of 
which have shown that there is a direct link between the properties of the 
nanoparticles and their bioavailability. Physicochemical properties of media 
solutions and the nanoparticles can also be linked. For example, increasing 
the ionic strength of a solution decreases the electrostatic forces between 
surfaces which would usually cause them to repel each other. This increases 
flocculation of nanoparticles, therefore encouraging the nanoparticles to bind 
to the biological surfaces (Fatisson et al., 2012). Coating the nanoparticle 
surface with proteins stabilises not only the nanoparticles but also the colloidal 
suspensions.  
1.4 Selenium  
 Jöns Jacob Berzelius discovered selenium in 1817 (Arner et al., 2012). 
Even at such an early stage he had noted the similarities between selenium 
and sulphur, which support the similarities in properties of selenocysteine-
containing proteins and those of cysteine containing peptides. Selenate and 
selenite are two oxidised forms of selenium, selenate being the most oxidised 
form (Butler, 2012). Selenate is easily reduced and is used as a respiratory 
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substrate by some bacterial species (Butler, 2012). It has been found that 
certain bacterial species can act as microbial factories for nanoparticle 
production, a good example being the bacterium T. selenatis, which depends 
on selenium nanoparticle production to respire selenium-containing oxyanions 
(Macy et al., 1993). 
1.5 Thauera selenatis 
 In 1983 there were environmental problems linked to the agricultural 
drainage waters in the San Joaquin Valley of California due to a high 
concentration of selenate, selenite and selenium in these waters (Saiki et al., 
1987). These high levels of toxic selenium and it’s oxyanions cause problems 
to aquatic organisms (Saiki et al., 1987), these problems could be aleviated 
by the reduction of selenate and selenite to elemental selenium (Macy et al., 
1989). Elemental selenium is less toxic than selenate (Debieux et al., 2011) 
and is easier to isolate and remove from contaminated water than the highly 
soluble selenate (Schroder et al., 1997). An organism able to reduce selenate 
to selenite under anaerobic conditions was isolated from the drainage waters 
in the San Joaquin Valley of California and incorrectly classified as a 
Pseudomonas species by Macy and co-workers (Macy et al., 1989). A further 
study carried out by Macy et al. classifies T. selenatis as a Gram-negative β-
proteobacterium able to respire anaerobically using selenium or nitrogen 
oxyanions as the electron acceptor (Macy et al., 1993). T. selenatis  is able to 
simultaneously, and anaerobically, reduce nitrate to nitrous oxide and 
selenate to selenite. Here, the reduction of selenate to selenite is performed 
by a dedicated selenate reductase (SerABC), which has been isolated from 
the bacterium and characterised (Schroder et al., 1997; Krafft et al., 2000). 
DeMoll-Decker and co-workers reported that selenite reduction to elemental 
selenium in T. selenatis was likely to be catalysed by a periplasmic nitrate 
reductase (DeMoll-Decker et al., 1993).  
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Figure 1.1: A schematic diagram to show the pathway for selenium export within the T. selenatis cell. 
1.6 Bacterial Selenate Respiration 
 Macy and co-workers state that T. selenatis is able to grow under 
anaerobic conditions using selenate as the sole electron acceptor. T. 
selenatis can concurrently reduce selenate and nitrate, suggesting that 
specific reductases act on each (Macy et al., 1993; DeMoll-Decker et al., 
1993). The reduction of selenate within T. selenatis occurs in the space 
between the inner and the outer membrane, the periplasmic compartment. 
The reduction of selenate in the periplasm is catalysed by a trimeric 
molybdoenzyme, SER, which is the selenate reductase (Schroder et al., 
1997).  This soluble, trimeric metalloenzyme has both molybdenum- and iron-
containing metal centres. It has three subunits; SerA, a catalytic component 
containing molybdenum and a [4Fe-4S] cluster (Krafft et al., 2000), SerB, an 
iron-sulphur protein containing one [3Fe-4S] and three [4Fe-4S] clusters 
(Dridge et al., 2007) and SerC, a haem b protein (Lowe et al., 2010). SerD is 
a cytoplasmic protein which assists with the assembly of SerA (Schroder et 
al., 1997; Butler et al., 2012). The reduction of selenate requires two electrons 
from quinol (the Q-pool) (Butler et al., 2012). A study carried out by Lowe et 
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al. found that a di-heme cytochrome of the cyt-c4 family provides an electron 
transfer pathway from the Q-pool to SerC (Lowe et al., 2006). The electrons 
are then transferred through the SerC and SerB to reach the catalytic 
molybdenum site in SerA, which is where the two-electron reduction of 
selenate to selenite occurs (Lowe et al., 2006). 
 Selenite reacts readily with thiols (Painter et al., 1941), and recent 
research by Debieux et al. (2011) suggests that glutathione (GSH), the most 
commonly reduced thiol in E. coli, could assist the bacterial intracellular 
reduction of selenite. The glutathione reacts with the selenite itself to produce 
a glutathione reductase, selenodiglutathione (GS-Se-SG). This 
selenodiglutathione is then further reduced to form an unstable 
selenopersulfide of the glutathione, GS-Se-, which then breaks down to form 
elemental selenium, Se0, and reduced glutathione (Debieux et al., 2011).  T. 
selenatis uses the intracellular reductant, glutathione, to detoxify selenite 
during the respiration of selenate, leading to a build up of selenium within the 
cell. It is thought to be necessary for the cell to expel the selenium from within 
using an export system (Debieux et al., 2011). Ogasawara et al. suggest that 
once selenite has reacted with GSH to produce elemental selenium within 
Rhodanese, a selenotrisulphide or perselenide intermediate could donate 
selenium to a protein and in this way provide a selenium delivery system 
(Ogasawara et al., 2001).  
 
   
 
 
 
 
 Transmission Electron Microscopy (TEM) has shown that as T. 
selenatis cells are grown on selenate, as the growth starts to enter the 
Figure 1.2: Transmission Electron Microscopy (TEM) micrograph of a T. selenatis cell taken from the 
mid-exponential growth phase showing an internal selenium particle (Butler et al., 2012). 
Internal 
selenium 
particle !
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stationary phase, elemental selenium particles gather in the cytoplasm (Figure 
1.2). Once growth stops, the particles are then observed outside of the 
cytoplasm, suggesting that they have been excreted from the cell (Butler, 
2012).  A recent study by Dobias and co-workers, focusing on E. coli, shows 
that in the presence of selenite, there is evidence of selenium interacting with 
various proteins (Dobias et al. 2011). This protein-nanoparticle interaction is 
said to be a controlling factor throughout the reduction of selenite, in particular 
where the selenium nanospheres are formed in T. selenatis (Butler, 2012).  
1.7 SefA 
 Debieux et al. (2011) analysed growth medium of T. selenatis following 
secretion of selenium nanoparticles from the cell cytoplasm during selenate 
respiration (Debieux et al., 2011; Butler et al., 2012). The protein profile 
showed a major protein at 94.5 kDa, which is believed to be specific to the 
reduction of selenite. It is also believed that this protein is related to the export 
of selenium from the cell and therefore it has been named Selenium Factor A 
(SefA) (Debieux et al., 2011). SefA has been cloned and expressed in E. coli 
and it has been shown that as selenite is reduced by glutathione, selenium 
nanoparticles are produced in vitro and SefA stabilises the formation of these 
nanoparticles. The amount of SefA present is directly proportional to the 
amount of time taken for T. selenatis to reduce selenite (Butler et al., 2012). 
The protein has been characterised and found to be made up of 961 amino 
acids and have a molecular mass of 95.4 kDa (Debieux et al., 2011).  SefA is 
unusual as the five amino acids; alanine, threonine, glycine, valine and 
aspartate make up 64.3% of the primary sequence (Butler, 2012). There are 
no cysteine residues in SefA, suggesting that selenium and SefA do not make 
disulphide bonds, but that they might form weaker interactions via carboxylate 
ligands. During the characterisation of the protein it was observed that the 
selenium nanoparticles grow to be up to 130 nm in diameter before they are 
excreted from the cell (see figure 1.3). Another question surrounding this 
research is how a particle so large can cross the membrane of the cytoplasm 
without damaging the cell, and whether or not there are specific factors 
controlling the size (Butler, 2012).  
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Figure 1.3: Transmission electron micrographs at time points of the growth of T. selenatis. 1 and 2 show 
the appearance of the selenium nanospheres at the late exponential growth phase. 3 and 4 show the 
stationary growth phases of T. selenatis, where the selenium nanospheres appear to have been 
excreted from the cell. Scale bar represents 200 nm. 
 Peptides and proteins such as bovine serum albumin (BSA) have been 
found to stabilise selenium nanoparticles via a non-specific interaction 
(Bucking et al., 2009). In Bucking’s investigation it has been found that the 
BSA ‘caps’ the surface of the nanoparticle, suggesting that a similar action 
could be followed by SefA in T. selenatis. If the SefA protein capped the 
selenium nanoparticles in T. selenatis, SefA could provide reaction sites for 
the assembly of the nanoparticles and in this way prevent particle aggregation 
(Debieux et al., 2011). It is believed that SefA is exported directly from the 
cytoplasm, as the protein does not contain an N-terminal signal sequence 
required for export to the periplasmic compartment of the cell (Debieux et al., 
2011). Targeting of the periplasmic compartment via a twin-arginine-
translocation (TAT) was also shown to be an unlikely pathway for the protein 
(Suwa et al., 1997; Debieux et al., 2011). It has been suggested that selenium 
nanospheres leave the cell via one of two secretion systems. Either the Type 
1 Secretion System (T1SS) due to the absence of cysteine residues in SefA 
(Delepelaire et al., 2004), or the Type 6 Secretion System (T6SS) as all other 
proteins secreted by this system are similarly not first translocated to the 
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periplasmic compartment due to the lack of an N-terminal signal sequence 
(Debieux et al., 2011).  
 Zhang et al. have discovered that a variety of different microorganisms 
are able to produce extracellular or intracellular selenium nanoparticles via the 
reduction of selenate and selenite in both aerobic and anaerobic conditions 
(Narasingarao et al., 2007; Ghosh et al., 2008; Prakash et al., 2009; Zhang et 
al., 2012). Micro-aerobic conditions were proven to be beneficial to the effects 
of certain microorganisms on the reduction of selenium oxyanions (Ike et al., 
2000; Dungan et al., 2003; Lee et al., 2007). It is easier to characterise 
extracellular selenium nanoparticles than it is intracellular, as they are easier 
to isolate from a culture. Oremland et al. studied three different selenate 
respiring bacteria, the investigation focused on whether they produced 
intracellular or extracellular selenium nanospheres (Oremland et al., 2004).  
Intracellular selenium deposits have been imaged by electron microscopy in 
various bacteria, both selenium respiring and selenium resistant, such as 
Wollinella succinigenes and Chromatium vinosum. Proposed export methods 
of extracellular selenium deposits have been cell lysis or a membrane efflux 
pump (Tomei et al., 1995; Losi et al., 1997).  Selenium deposits have been 
observed accumulating in cytoplasmic compartments of cells, this overload of 
selenium is rarely tolerated.  This calls for the exportation of selenium 
nanospheres from the cells (Zhang et al., 2012).  This export of selenium 
requires energy, therefore oxygen or another electron acceptor must be 
present to allow for respiration which releases energy. Zhang and co-workers 
conducted a study focusing on the reduction of selenite to elemental selenium 
under oxygen-limited conditions, assisted by yeast cells (Zhang et al., 2012). 
It has been suggested that these yeast cells transport the over loaded 
selenium out of the cells under such conditions leading to the formation of 
extracellular selenium nanoparticles (Zhang et al., 2012). Early studies 
showed selenium to be present in the cell wall and membrane, the ribosomal 
fraction and primarily in the cytoplasm. More recently locating the position of 
elemental selenium within the cell has become more accessible due to 
electron microscopy. 
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1.8 The production of selenium nanoparticles 
 Many nanoparticles have properties which are specific to certain 
organisms, for example the aquatic bacteria Leptothrix ochracea oxidise iron 
to produce iron oxide nanoparticles (Hashimonto et al., 2007). The 
biologically-derived iron oxide nanoparticles produced are ocher deposits in 
irrigation canals, natural streams and ditches (Spring et al., 2006; Emerson et 
al., 2010). Iron oxide nanoparticles isolated from a water purifying tank in 
Japan (Hashimonto et al., 2012) have been shown to have applications in 
carriers for cell culture (Seno et al., 2012) and battery electrodes (Takada et 
al., 2008). Another example of organism-specific nanoparticles are selenium 
nanospheres produced in T. selenatis during selenate respiration. Selenate is 
reduced in two steps, via selenite, eventually producing elemental selenium 
(Debieux et al., 2011). Selenium is an element in group 16 of the periodic 
table (a chalcogen) which can exist in four oxidation states; -2, 0, +2 and +4 
(Butler et al., 2012).  It is the two soluble oxyanions, (oxidation states +4 and 
+6), which are involved in bacterial selenate respiration in T. selenatis. The 
oxidised selenium species with an oxidation state of +4 is selenite (SeO32-) 
and of +6 is selenate (SeO42-) (Butler et al., 2012; Butler, 2012). The bacterial 
respiration process is driven by metalloproteins. Metalloproteins differ from 
normal proteins in that they bind complex redox-active, metal containing 
cofactors that can assist electron transfer and therefore catalyse the 
reductions involved in respiration (Butler, 2012).  Selenate, the most oxidised 
form of non-elemental selenium, is first reduced using two electrons to 
selenite, which is then reduced further to form elemental selenium (Equation 1 
& 2). 
SeO42- + 2H+ + 2e- ! SeO32- + H2O 
Equation 1: The reduction of selenate to produce selenite (Richardson et al., 2000). 
and 
SeO32- + 6H+ + 4e- ! Se0      + 3H2O 
Equation 2: The reduction of selenite to produce elemental selenium (Lloyd et al., 2003). 
! 23!
The elemental selenium (Se0) produced by T. selenatis cells is usually 
observed as an amorphous red precipitate in batch cultures. However, higher 
resolution at sub-microscopic scale reveals insoluble, uniform particles that 
either congregate in the cell or in the surrounding growth medium. Typically 
there is only one electron dense selenium deposit in each cell, which can be 
isolated by filtering the growth culture through a fine filter (Butler et al., 2012).  
It is desirable to obtain these selenium nanospheres in isolation due to the 
semiconductor and photochemical properties of elemental selenium. These 
properties lend to their use in solar cells, photocopiers and photographic 
exposure meters (Johnson et al., 1999). 
 
 
  
 
 
 
Selenium also has important functions within the body such as the formation 
of selenocysteine and selenoproteins, used to remove products of damage 
caused by free radicals and reactive oxygen species, therefore bacteria often 
uptake insoluble selenium within the cell (Heider et al., 1993; Butler et al., 
2012). This leads to a build up of toxic selenium within the cytoplasm, a 
situation that is unsustainable in selenate-respiring organisms (Butler, 2012).  
A question that surrounds this area of research is how do the bacteria deal 
with the insoluble selenium nanoparticles. The insoluble selenium deposits in 
question have been observed in the cytoplasm in the bacterium, as seen in 
Figure 1.4, suggesting that this is the site of selenite reduction (Butler et al., 
2012).  
Figure 1.4: TEM micrograph of a secreted selenium nanosphere from a T. selenatis cell. Size bar 
represents 50 nm. (Butler et al., 2012). 
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1.9 The abiotic production of selenium nanoparticles 
 Although there is a lot of evidence of selenium nanospheres being 
produced biologically via the reduction of selenate and selenite, chemical 
synthesis is also able to produce selenium particles similar in both size and 
properties (Oremland et al., 2004). A study involving E. coli producing 
glutathione reductase subsequently found that cells grown in the presence of 
selenite also produced superoxide dismutase. This suggested that superoxide 
anions (O2-) were also produced and lead Kessi and co-workers to investigate 
the chemical reduction of selenite by glutathione (Kessi et al., 2004).  Ganther 
proposed the following set of equations to describe the reaction of selenite 
with glutathione, as selenodiglutathione is a good substrate for glutathione 
reductase (Ganther et al., 1971). 
 GS-Se-SG + NADPH  ! GSH + GS-Se- + NADP+ 
 Equation 3: The reaction of selenodiglutathione (Ganther et al., 1971) 
 GS-Se- + H+  ! GSH + Se0 
 Equation 4: The reduction of unstable selenopersulphide (Ganther et al., 1971) 
Equation 4 shows the formation of elemental selenium and reduced 
glutathione from the unstable selenopersulphide of glutathione. Kessi et al. 
found that the abiotic reaction that formed the selenodiglutathione was similar 
to the biological reaction, however much more selenite was reduced in the 
abiotic reaction (Kessi et al., 2004). In the biological reaction the reduced 
glutathione is regenerated much like a catalyst however this is not the case in 
the abiotic reaction. Chemically, there is a build up of oxidised glutathione 
(GSSG), causing problems for the reaction and therefore slowing down the 
reaction rate (Kessi et al., 2004). The breakdown of the unstable 
selenopersulphide of glutathione to elemental selenium and reduced 
glutathione follows the same process in both the biological and the chemical 
process. 
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1.10 Aims and objectives 
 Research shows that bacteria can play a major part in the reduction of 
selenium oxyanions to elemental selenium. It is important to understand the 
role that peptides play in this process and how they interact with the elemental 
selenium. This project builds on previously published research focussing on 
proteins secreted during selenium production by the model selenite respiring 
organism T. selenatis. The aims of this present study are: 
• To express and purify His-SefA and His-SefA-His. 
• To generate selenium nanospheres in vitro.  
• To analyse the selenium nanospheres in collaboration with NanoSight 
Ltd via NTA. 
• To cleave the N-terminal His-tag from the His-SefA protein to form a 
non-His-tagged form of the SefA protein. 
• To crystalise His-SefA-His in order to resolve the structure of the SefA 
protein from T. selenatis. 
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2 Materials and Methods 
2.1 Expression of His-SefA and His-SefA-His 
 Previous work (Debieux et al., 2011) isolated a 94.5 kDa protein, SefA, 
associated with the production of elemental selenium during selenate 
respiration. Two coding sequences for the SefA protein from T. selenatis have 
been cloned into the pET-33b(+) expression vector. This allowed expression 
of each recombinant protein from E. coli host and subsequent purification 
from cell-free extracts using affinity chromatography. The first, pET-33b/His-
SefA, is an expression construct for the SefA protein with a His-tag attached 
to the N-terminus and the second, pET-33b/His-SefA-His, is a construct for 
SefA expression with a His-tag on both the N-terminus and the C-terminus. 
Cells (from glycerol stock) containing the relvant expression construct for 
either His-SefA or His-SefA-His were added to 100 mL Lysogeny Broth (LB) 
containing kanamycin (50 µg/mL) and chloramphenicol (35 µg/mL). The 
culture was grown overnight with agitation (250 rpm) at 37°C. 10 mL of this 
overnight culture was added to 500 mL of fresh LB media and incubated 
under agitation at 250 rpm at 37°C until the optical density OD600nm was 0.4. 
At this point the culture was cooled for 30 minutes, Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM 
before incubating the culture overnight with agitation (250 rpm) at 20°C. The 
cells were then extracted by centrifugation at 5,000 x g at 10°C for 15 
minutes, the supernatant discarded, before resuspension in 25 mL of buffer 
Tris-HCl (pH 7.0), 0.5 M NaCl, 50 mM Imidazole. The cells were stored at -
20°C until further use. 
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Table 2.1: Bacterial strains and plasmids used in this study 
Strains and 
Plasmids 
Characteristics Reference 
E. coli BL21-
CodonPlus®(DE3)-
RIPL 
F–, dcm, ompT, hsdS (rB– mB–), gal, 
λ(DE3)  
 
Stratagene 
T. selenatis 
(ATCC55363) 
Selenate respiring, β-subclass of 
proteobacteria 
Macy et al., 
1993 
pET33b Kanr, lacI gene, IPTG inducible, PT7 Novagen 
2.2 Purification of His-SefA and His-SefA-His 
2.2.1 Cell Lysis 
 Cells were lysed via sonication with a deflection of 10 microns using a 
programme of 25 seconds on and 35 seconds off, repeated for six cycles. The 
cell debris were then clarified by centrifugation at 20,000 x g at 4°C for 30 
minutes The supernatant was retained and either used immediately or frozen 
at -20°C.  
2.2.2 Nickel affinity chromatography 
 A 20 ml affinity column containing 10 ml ProBondTM Nickel-Chelating 
Resin was equilibrated with three column volumes of buffer A. The sample 
was then added to the column and left to bind under gentle agitation for 20 
minutes before the resin was left to settle by gravity. The affinity column was 
washed with two column volumes of buffer A (2.2.3) to remove any unbound 
sample before one column volume of buffer B (2.2.3) was applied to elute the 
bound sample. Fractions were collected at the wash steps and elution steps 
and analysed using SDS-PAGE. 
2.2.3 Buffer preparation for purification 
Buffer A – 50 mM Tris-HCl, pH 7.0, 0.5 M NaCl, 100 mM imidazole 
Buffer B – 50 mM Tris-HCl, pH 7.0, 0.5 M NaCl, 1 M imidazole 
Buffer C – 10 mM HEPES, pH 7.0, 0.5 M NaCl 
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2.2.4 Gel filtration chromatography 
 A Superdex 200 HiLoad 16/60 (GE Healthcare) 120 ml gel filtration 
column was equilibrated with one column volume of buffer C (2.2.3) at a flow 
rate of 1 ml/min.  The sample was loaded and eluted over one column volume 
collecting fractions. Collected fractions were analysed using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
 The Superdex 200 gel filtration column was calibrated with the 
following protein standards: thyroglobulin  (669 kDa), apoferritin (443 kDa), β-
amylase (200 kDa), bovine serum albumin (66 kDa) and carbonic anhydrase 
(29 kDa). These protein standards were applied to the Superdex 200 gel 
filtration column equilibrated in one column volume of 50 mM Tris-HCl, pH 
7.5, 100 mM KCl and eluted with this same buffer. The large polymer blue 
dextran (2000 kDa) was used to determine the void volume (Vo = 39.88 ml). 
The elution profile (figure 2.1) was used to determine an approximate 
molecular mass for the proteins using the following equation: 
퐾푎푣=푉푒−푉0푉푡−푉0 
Equation 5: Calculation of Kav. Ve = elution volume of the protein, V0 = void volume of the column 
(39.88 ml), Vt = total volume of the column (120 ml).  
A rearrangement of the equation of the line of the calibration curve allows the 
log molecular weight to be calculated: 
푙표푔푀푊=0.9028−퐾푎푣0.293 
Equation 6: Calculation of the log of the molecular weight.  
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Figure 2.1: The elution profile of protein standards carbonic anhydrase, BSA, amylase, aptoferritin and 
thyroglobulin (left to right). 
2.3 SDS-PAGE 
 Protein was analysed by SDS-PAGE using pre-cast NuPAGE® 
Novex® 10% Bis-Tris Gels as per manufacturers instructions. 
2.3.1 Stock Solutions 
NuPAGE® LDS Sample Buffer (4X):-  40-70% Glycerin 
       7-13% Sulfuric acid,  
       monododecyl ester,  
       lithium salt 
NuPAGE® Reducing Agent (10X):-  500 mM Dithiothreitol 
NuPAGE® MOPS SDS Running Buffer (20X):- 50 mM MOPS 
       50 mM Tris Base 
       0.1% SDS 
       1 mM EDTA 
       pH 7.7 
NuPAGE® Antioxidant:-    10-30% Dimethylformamide 
       10-30% Sodium bisulphate 
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Expedeon Instant Blue Protein Stain:-  0.05% Coomassie Brilliant  
       Blue 
       2% Ethanol 
       5% Solubilisers 
       12% Phosphoric acid 
2.3.2 Sample Preparation 
 5 µl of 4X NuPAGE® LDS Sample Buffer plus 2 µl of 10X NuPAGE® 
Reducing Agent was added to 13 µl of each sample. The sample buffer and 
reducing agent denature the proteins and reduce the protein disulphide bonds 
ready for polyacrylamide gel electrophoresis (PAGE). The mixture was heated 
at 70°C for 10 min to fully denature the protein before loading it onto the gel.  
2.3.3 SDS-PAGE Running 
 The gel apparatus was set up following the manufacturer’s instructions 
using an XCell SureLock® Mini-Cell. The buffer chamber was filled with 1X 
NuPAGE® MOPS SDS Running Buffer, with 500 µl of NuPAGE® Antioxidant 
in the inner chamber. The prepared samples were loaded onto a 10% Bis-Tris 
NuPAGE® gel along with 5 µl of a molecular weight marker (SeeBlue® Plus2 
Pre-Stained Standard). The gel was run at 200 V for 50 min.  
2.3.4 Gel Staining Procedure 
 The SDS-PAGE gel was removed from the gel apparatus and left to 
stain for 1 hr in Expedeon Instant Blue Protein Stain. The gel was then left to 
destain in double distilled water (ddH2O) for 1 hr. 
2.4 Western Blot Analysis 
 Samples were separated on a 10% Bis-Tris SDS gel and the gel was 
set up in the XCell II™ Blot Module following manufacturer’s instructions for 
the transfer of proteins onto a nitrocellulose membrane ready for 
immunodetection. The blotting apparatus was cleaned with distilled water 
(dH2O) and methanol and then set up with three layers of 3 mm blotting 
paper, one layer of filter paper, the SDS gel, one layer of nitrocellulose 
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membrane, one layer of filter paper and a further three layers of 3 mm blotting 
paper. All blotting paper, filter paper and transfer membrane was pre-soaked 
in 1 x transfer buffer (25 mM Tris-HCl pH 7.5, 200 mM glycine). The proteins 
were transferred to the nitrocellulose membrane at 30 V for 60 min. The 
nitrocellulose membrane was then soaked in 10-20% dried milk diluted in 1 x 
wash buffer for 30-60 min with agitation.  
5 x Wash Buffer 
1M Tris-HCl pH 5.6   50 ml/L 
NaCl     146 g/L 
Tween 20     2.5 ml/L 
 The nitrocellulose membrane was then washed 3 x 5 min in 1 x wash 
buffer before incubation overnight at 4°C with the primary antibody 
Monoclonal Anti-polyHistidine antibody produced in mouse (4 µl diluted in 20 
ml of 1 x wash buffer). The membrane was then washed twice quickly, once 
for 15 min, then twice for 5 min in larger volumes of 1 x wash buffer. The 
nitrocellulose membrane was then incubated at room temperature with 
agitation for 1 hr with the secondary antibody Anti-Mouse IgG Alkaline 
Phosphatase (AP) Conjugate (4 µl diluted in 20 ml of 1 x wash buffer). The 
membrane was then washed again twice quickly, once for 15 min, then twice 
for 5 min in larger volumes of 1 x wash buffer. The nitrocellulose membrane 
was then drained of wash buffer and incubated at room temperature with 
agitation in 10 ml of Western Blue stabilized substrate for Alkaline Phosphate 
for 5 min. After 5 min bands should begin to develop on the nitrocellulose 
membrane. 
2.5 Crystallisation of His-SefA-His 
2.5.1 Preparation of protein for crystallisation 
 After gel filtration chromatography, the fractions containing purified 
protein were concentrated to ∼ 10 mg/ml as in methods 2.4.  
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2.5.2 Initial crystal trials 
 Microbatch crystallisation trials were set up in a Hampton Research 96 
well plate using an Oryx 6 crystallization robot (Douglas Instruments, UK). A 
JCSG screen was used (Molecular Dimensions Laboratories). The final 
droplet volume was varied between 1 µl and 2 µl depending on how much 
protein solution was available. The droplet contained a 50:50 ratio of protein 
to screen and each droplet was then covered with Al’s oil (50:50 mix of silicon 
oil to paraffin). The plates were stored at 18 °C and regularly checked for 
crystal growth using a light microscope.  
2.5.3 Preparing crystals for data collection 
 Crystals were frozen using a cryo-protectant (10 mM HEPES Na salt, 
pH 7.5, 0.1 M CAPS, 1 M NaBr, 40 % MPD). The crystals were removed from 
the droplet and placed in the cryo-protectant before being frozen directly in 
liquid nitrogen and taken to the Diamond Light Source (Oxford, UK). This is 
the UK’s national synchrotron facility where data is collected under cryo 
cooled conditions. 
2.6 Protein concentration determination 
 Proteins were concentrated using a Millipore Amicon Ultra centrifugal 
spin concentrator at 5000 x g and 4°C. 
2.6.1 Bio-Rad protein assay 
 The Bio-Rad protein assay was carried out using a microplate reader 
following the standard procedure for microtiter plates. The dye reagent was 
prepared by diluting 1 part Dye Reagent Concentrate to 4 parts dd. H2O. This 
was filtered through a Minisart® Plus syringe filter (0.2 µm) and kept at room 
temperature. Five dilutions of a protein standard, Bovine Serum Albumin 
(BSA), were prepared: 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml and 0.5 
mg/ml. The protein solutions were assayed in triplicate. 10 µl of each standard 
and sample solution was pipetted into separate microtiter plate wells. 200 µl 
of diluted dye reagent was added to each well. The sample and reagents 
were mixed well using a microplate mixer. The microtiter plates were 
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incubated at room temperature for at least 5 min but for no longer than 1 hr 
Absorbance was measured at 595 nm. 
2.6.2 NanoDrop 
 Protein concentration was determined using a NanoDrop 2000c UV-Vis 
Spectrophotometer (A280). This technology requires blanking with the protein 
buffer then using 2 µl of sample to detect protein concentration. 
2.7 In vitro formation of selenium nanospheres 
 Selenium nanoparticle formation assays were performed in 50 mM 
Tris-HCl buffer (pH 8), supplemented with protein, 5 mM reduced glutathione 
and 0.75 mM selenite at room temperature in quartz cuvettes. The reaction 
was carried out under anaerobic conditions so all solutions were sparged with 
nitrogen including the cuvette itself prior to reduction with reduced glutathione. 
The formation of selenium nanospheres was measured spectrometrically at 
400 nm over a period of 400 s. The selenium nanoparticle formation assays 
were repeated at a range of protein concentrations (0.5 µg/ml – 50 µg/ml). 
2.8 Nanoparticle analysis in collaboration with NanoSight Ltd 
2.8.1 Nanoparticle Tracking Analysis (NTA) 
 NTA tracks the Brownian motion of nanoparticles in liquid suspension 
on a particle-by-particle basis. The Stokes-Einstein equation (equation 7) 
relates Brownian motion to particle size.   
 
Equation 7: Stokes-Einstein equation where Dt = particle diffusion coefficient, T = temperature (Kelvin), 
KB = Boltzmann’s Constant, η = solvent viscosity and d = the sphere-equivalent hydrodynamic diameter. 
 The NTA was carried out using a NanoSight LM10-HS instrument, 
which uses a laser light to illuminate the nanoparticles within a 0.3 ml sample 
introduced to the viewing unit. Results were displayed as a frequency size 
distribution graph and output to spreadsheet. Still video clips showing 
nanoparticles were also obtained. 
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2.8.2 Zeta Potential 
 Zeta potential was measured using a ZetaSight system which allowed 
the zeta potential of nanoparticles in aqueous suspension to be measured on 
a particle-by-particle basis. An electric field was applied to the nanoparticles, 
which caused them to move and the NanoSight technique recorded the 
apparent drift velocity of each particle. 
2.9 Protein modification 
 Both recombinant proteins, His-SefA and His-SefA-His were modified 
by cleaving the N-terminal His-tag off of the protein to form both SefA and 
SefA-His. This was carried out using a Thrombin CleanCleave™ Kit from 
Sigma-Aldrich.  
2.9.1 Sample Preparation 
 All protein to be modified must be previously purified by nickel affinity 
chromatography and then exchanged into 50 mM Tris-HCl, pH 8.0, with 10 
mM CaCl2. 
2.9.2 Washing Resin 
 The thrombin-agarose resin (thrombin-agarose 50 % suspension in 50 
% glycerol, 20 mM Tris-HCl, pH 8.2) was thoroughly resuspended to make a 
homogeneous slurry. A 100 µl aliquot was removed and gently spun in a 
microcentrifuge at 500 x g (2,500 rpm) for 10 min to pellet the resin. The 
supernatant was poured off carefully. 500 µl of 1 X cleavage buffer (50 mM 
Tris-HCl, pH 8.0, 10 mM CaCl2) was added to gently resuspend the pellet by 
inverting the tube. This was then centrifuged at 500 x g for 10 min and the 
supernatant was poured off carefully. This washing step was repeated. 
2.9.3 Cleavage Reaction 
 100 µl of 10 X cleavage buffer (500 mM Tris-HCl, pH 8.0, 100 mM 
CaCl2) was added to the centrifuged beads to gently resuspend them. 1 mg of 
protein was added and the final volume was brought to 1 ml with water. The 
cleavage reaction was incubated with gentle agitation at room temperature for 
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24 hr. Aliquots were removed at 1, 2, 4, 6 and 24 hours and gently centrifuged 
to remove the resin and analyze the supernatant for cleavage by SDS-PAGE 
and Western Blotting. 
2.9.4 Recovery of the fusion protein 
 The cleavage reaction was transferred to the column, once the resin 
had settled the eluent was drained and collected.  The resin was rinsed with 5 
bed volumes of 1 x cleavage buffer and the eluent collected. All eluents were 
combined. 
2.9.5 Separating the protein from the cleaved His-tag 
 The His-tags need to be separated from the protein that has undergone 
the cleavage reaction.  
 The separation of His from SefA was carried out collecting the sample 
flow through from a nickel affinity column. A 10 ml nickel affinity column was 
washed with 4 x 10 ml buffer A (2.2.3). The protein sample was added and 
agitated for 20 min. The column was left to settle before the protein was 
collected and the protein concentration was determined via NanoDrop (2.7.2). 
The column was washed with 2 x 10 ml buffer B to remove the His-tags.  
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3 Probing protein-mediated assembly of selenium 
nanospheres by recombinant SefA 
3.1 Introduction 
 It has been found that in the selenate respiring bacterium T. selenatis, 
solid selenium deposits are produced during selenate respiration (Macy et al., 
1989). This precipitated selenium is red and the deposits are spheres with a 
diameter of approximately 130 nm (Butler et al., 2012).  Analysis of the growth 
medium over time has shown that these selenium nanospheres are exported 
out of the cell during the exponential growth phase and it is thought that a 
selenium export factor protein facilitates this exportation. This protein has 
been calculated to have a mass of 94.5 kDa and has been previously cloned 
and expressed in E. coli and the recombinant His-tagged protein purified 
(Debieux et al., 2011).  
 Two recombinant His-tagged forms of SefA have been previously 
expressed and purified in E. coli, the aim of this work is to see what role the 
recombinant, non-His-tagged SefA protein (rSefA) plays in selenium 
nanosphere assembly. It is possible that the rSefA protein will behave more 
similarly to the protein isolated from the growth medium of T. selenatis. 
Sequence inspection of the translated open reading frame for SefA, within the 
pET-33b/His-SefA vector, reveals that the N-terminal His-tag of His-SefA may 
be cleaved using a Thrombin proteolytic site.  
 Upon the cleavage of the N-terminal His-tag a new form of the SefA 
protein will be produced with no His-tags. The non-tagged protein and the 
cleaved His-tags will be separated via nickel affinity chromatography before 
investigating the effect of this native protein on selenium nanosphere 
assembly. Selenium nanoparticles can be produced in vitro to form similar 
particles to those produced in the selenate respiring bacterium T. selenatis. In 
this study a variety of different concentrations of rSefA will be used to 
investigate what effect the protein has on the assembly and properties of 
these nanospheres. 
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3.1.1 Specific aims and objectives 
• Express and purify the recombinant His-SefA protein. 
• Cleave the N-terminus His-tag from the His-SefA protein to produce the 
non-His-tagged SefA form, rSefA. 
• Investigate the effect of rSefA protein on selenium nanosphere 
formation via NTA. 
3.2 The preparation of rSefA from His-SefA 
 To obtain a ‘His-tag free’ form of the SefA protein (rSefA), the N-
terminus His-tag had to be cleaved from the His-SefA form of the protein. 
Looking at the pET-33b(+) vector it can be seen that the N-terminus His-tag 
could be cleaved at the Thrombin site and carried out using a Sigma Aldrich 
Thrombin CleanCleave™ Kit.  
 Cells harbouring a recombinant form to express the His-SefA protein 
were over-expressed in E. coli BL21 CodonPlus (DE3)-RIPL cells. A culture 
containing the cells expressing the His-SefA protein, kanamycin and 
chloramphenicol in LB broth was grown overnight at 37°C with agitation. 
Fresh LB media was inoculated with this overnight culture and incubated 
under agitation at 37°C until the optical density (OD600nm) was 0.4. Once this 
optical density had been reached, the culture was cooled for 30 mins prior to 
the addition of IPTG. The culture was then incubated once more under 
agitation at 20°C. The cells were then extracted by centrifugation and 
resuspended before the cells were lysed by sonication and clarified. The His-
SefA protein was then purified using nickel affinity chromatography, where the 
purified protein was eluted in 50 mM Tris-HCl, pH 7.0, 0.5 M NaCl, 1 M 
imidazole (figure 3.1).  
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 This purified protein was added to the thrombin-agarose resin, 
following the procedure for the Thrombin CleanCleave™ Kit (materials and 
methods 2.10) and the reaction was incubated for 24 hours at room 
temperature with gentle agitation. 100 µl aliquots were taken at time points of 
1, 2, 4, 6 and 24 hours and analysed by SDS-PAGE to monitor the progress 
of the cleavage reaction (figure 3.2). A major protein band was seen on the 
developed SDS-PAGE gel at approximately 95 kDa, consistent with the 
expected size and thus the presence of SefA. As the rSefA protein has no 
His-tags attached to either the N-terminus or the C-terminus, Western Blot 
analysis (materials and methods 2.5) was used to confirm the cleavage of the 
N-terminal His-tag from His-SefA. The removal of the N-terminal His-tag can 
be seen in figure 3.3. 
 
 
 
Figure 3.1: SDS-PAGE analysis of His-SefA purified by nickel affinity chromatography. Lane 1 = Pre-
Stained protein standard. Lanes 2-11 show elutions from nickel affinity chromatography. !
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Figure 3.2: SDS-PAGE analysis of the cleavage of the N-terminal His-tag from His-SefA (1 mg/ml). Lane 
1 shows Pre-Stained protein standard, lane 2 shows the cleavage reaction at t=1 hr, lane 3 shows t=4 
hr, lane 3 shows t=6 hr, lane 4 shows t=24 hr and lane 5 shows rSefA. 
 
 
 
 
 
 
 
 
 
Figure 3.3: Western Blot analysis of the cleavage of the N-terminal His-tag from His-SefA. Lane 1 shows 
Pre-Stained protein standard, lane 2 shows the cleavage reaction at t=1 hr, lane 3 shows t=4 hr, lane 3 
shows t=6 hr, lane 4 shows t=24 hr and lane 5 shows rSefA. 
!!!!!!1!!!!!!!2!!!!!!!!3!!!!!!!!4!!!!!!!!!5!!!!!!!6!!!!Mw!(kDa)!! 191!! 97!!!!!
! 64!
! 51!!! 39!!! 28!
!!!!!!1!!!!!!!2!!!!!!!!3!!!!!!!!4!!!!!!!!!5!!!!!!!6!!!!Mw!(kDa)!! 191!! 97!!!!!
! 64!
! 51!!! 39!!! 28!
! 40!
3.3 In vitro formation of selenium nanospheres stabilised by 
 rSefA 
 Preliminary studies showed that Se0 produced in vitro had a wide 
range of sizes, unlike the selenium deposits produced in T. selenatis (Debieux 
et al., 2011). The red selenium deposits were formed during the anaerobic 
reaction between reduced GSH (5 mM) and selenite (0.75 mM). It was 
necessary for the molar ratios of GSH:selenite to be > 4:1 to ensure that the 
GS-Se-SG was reduced to GSSeH to be reduced further to Se0 (Debieux et 
al., 2011). The formation of selenium nanospheres was measured 
spectrometrically at 400nm in the presence of the rSefA protein (0.5 µg/ml, 1 
µg/ml, 5 µg/ml, 10 µg/ml and 50 µg/ml). The reaction was performed in 
triplicate at each different protein concentration and the formation of these 
selenium nanoparticles as a function of time can be seen in figure 3.4. A plot 
of final absorbance plotted against protein concentration can be seen in figure 
3.5. 
 
Figure 3.4: The formation of selenium nanospheres measured spectrometrically at 400 nm. This is an 
average representation of all three runs at different protein concentrations. 
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Figure 3.5: A plot of final absorption against protein concentration. This is an average representation as 
the reaction was run in triplicate at each protein concentration. 
 Figure 3.4 shows an increase in absorbance with time as the 
concentration of rSefA increases. The initial formation of particles (0-5 s) 
shows a slightly slow rate of formation before this rate increases at 
approximately 5 s. The higher the concentration of the protein the quicker the 
higher rate of formation is initiated. Figure 3.5 shows a general trend of an 
increase in final absorption as the protein concentration increases. 
3.4 Nanoparticle tracking analysis of selenium nanospheres 
 stabilised by rSefA 
 Nanoparticle tracking analysis of the selenium nanospheres tracks the 
Brownian motion of each nanoparticle individually and, with application to the 
Stokes-Einstein equation, allows particle size to be determined. Nanoparticle 
tracking analysis was applied to each sample of selenium nanospheres 
produced as described in 3.3. Nanoparticle tracking analysis produces a video 
of the nanoparticles in suspension, a time frame of the selenium nanoparticles 
stabilised by 5 µg/ml rSefA can be seen in figure 3.6.  
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 Plots of concentration against particle size in triplicate of selenium 
nanosphere samples can be seen in figures 3.7, 3.8 and 3.9 and a plot of 
mean particle size against protein concentration in figure 3.10. Three separate 
reactions were analysed individually. 
 Figures 3.7-3.9 show that in general, at low concentrations of rSefA 
there is a narrow size distribution of selenium nanoparticles (25-150 nm). 
However, at higher concentrations of the protein the size distribution is a lot 
broader (25-250 nm). Figure 3.8 shows a slight variation as it is in fact 5 µg/ml 
of rSefA, which produces selenium nanospheres with the most narrow size 
distribution. Figure 3.10, showing mean particle size against protein 
concentration, shows that as protein concentration increases, the mean 
particle size also increases. The ‘error bars’ shown in the figure do not 
represent error, but the size distribution of the particles formed at each protein 
concentration. Again here you can see that the size distribution is increasing 
in range as the protein concentration increases. 
 
Figure 3.6: A still image of selenium nanoparticles stabilised by 5 µg/ml rSefA. The dots represent 
selenium nanospheres produced in-vitro in the presence of 5 µg/ml rSefA moving due to Brownian 
Motion. 
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Figure 3.7: Particle size against particle concentration from NTA for reaction 1 over a range of protein 
concentrations. 
 
Figure 3.8: Particle size against particle concentration from NTA for reaction 2 over a range of protein 
concentrations. 
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Figure 3.9: Particle size against particle concentration from NTA for reaction 3 over a range of protein 
concentrations. 
 
Figure 3.10: An average representation of mean particle size against protein concentration for selenium 
nanospheres produced in the presence of rSefA. 
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3.5 Discussion 
 Preliminary studies (Debieux et al., 2011) showed that His-SefA was 
not capable of forming selenium nanospheres with a controlled narrow size 
distribution in vitro as seen in T. selenatis. This study forming selenium 
deposits in the presence of the rSefA protein focuses on investigating whether 
there is a trend in the size and size distribution of the nanospheres produced. 
The rSefA protein was formed by the cleavage of the N-terminal His-tag of 
His-SefA at the Thrombin site. This form of the protein, containing neither an 
N-terminal or C-terminal His-tag, was added to the reaction between reduced 
GSH and selenite to determine the effect of it’s presence on the resulting 
selenium nanospheres. The reaction was monitored spectrometrically and a 
general trend can be seen of an increase in absorbance with time as the 
concentration of rSefA increases. This increase in absorbance suggests that 
more red selenium nanospheres have been formed and so an increase of 
protein concentration sees an increase in the amount of selenium formed. As 
the concentration of rSefA present increased, the particles formed during the 
reaction had intensified in colour. The plot of final absorbance against protein 
concentration further confirms this as it shows an increase in final absorbance 
as protein concentration increases.  
 The data sets collected from NTA allowed particle size against 
concentration of the particle size to be plotted and therefore enabled the 
distribution in size of the particles to be seen. The nanospheres formed at the 
lowest concentration of rSefA (0.5 µg/ml) showed a narrow size distribution, 
with a high concentration of particles between 50-100 nm. As the protein 
concentration increased, the size distribution of the nanoparticles broadened, 
with selenium nanospheres produced in the presence of 50 µg/ml rSefA 
showing a lower concentration of particles over a larger scale of 25-250 nm. A 
trend can be seen of increasing particle size with increasing protein 
concentration, as well as an increase in final absorbance and an increase in 
particle size. This suggests that at higher protein concentration not only is 
more selenium produced but these selenium nanospheres are also larger 
than those produced at lower protein concentrations. Debieux and co-workers 
found that selenium nanospheres secreted by T. selenatis during selenate 
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respiration were approximately 130 nm in diameter (Debieux et al., 2011). By 
contrast, these selenium nanospheres produced in vivo in the presence of the 
recombinant SefA protein produce selenium nanospheres ranging from a 
mean particle size of ~85 nm, at the lowest protein concentration (0.5 µg/ml), 
and ~167 nm at the highest protein concentration (50 µg/ml). It has been 
shown that nanoparticles produced in vitro in the presence of 10 µg/ml rSefA 
are approximately 130 nm in size. This could suggest that T. selenatis has an 
internal SefA concentration of 10 µg/ml to produce stable nanoparticles of this 
size.  
 Bucking and co-workers have investigated how nanoparticles are 
stabilised by protein interactions (Bucking et al., 2009). They have suggested 
that BSA acts as a stabilising ligand which coats quantum dots. If SefA 
‘coated’ the selenium nanoparticles in this way perhaps it too would have a 
stabilising effect on these elemental selenium deposits. SefA could be coating 
the selenium nanospheres and self-assembling it’s protein corona into a 
nano-cage (Fletcher et al., 2013). Fatisson et al. discovered that surface 
charge has an effect on the bioavailability of nanoparticles (Fatisson et al., 
2011). The addition or removal of a His-tag from the SefA protein could be 
affecting the overall surface charge of the SefA-selenium nano-cage. 
Although I don’t believe that the removal of the His-tag would have an effect 
on the SefA protein, I do think that it could have an effect on the nanocage 
itself.  
 SefA homologues have been found in two strains of Nitrosomonas and 
figure 3.11 shows the sequence alignment of SefA with these two strains 
(AL212 and Is79A3). Strain AL212 has been used for ammonium sulphate 
reduction (Suwa et al., 1997) and other strains have been shown to produce 
intra- and extracellular particles. The overall identity between the protein and 
the two Nitrosomonas strains is low however between the first 25 N-terminal 
residues there is 60% identity (Butler et al., 2012). Suwa and co-workers have 
shown electron micrographs showing extracellular particles which could be 
acting in a similar way to the selenium deposits produced in T. selenatis 
(Suwa et al., 1997). 
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 This suggests that the N-terminus of SefA could be important in the 
assembly of the protein and could have a key role in the protein-protein 
interactions, or indeed the protein-nanoparticle interactions. Del Pino and co-
workers discuss how protein adsorption onto nanoparticles resembles ligand 
binding (Del Pino et al., 2013). This could suggest that the N- and C-terminal 
His-tags are acting as ligands attached to the SefA protein. If so, this could 
affect the way in which particles assemble when the N-terminus and C-
terminus of SefA are blocked in His-SefA and His-SefA-His. The removal of 
this N-terminal His-tag and the exposure of the N-terminus of SefA could be 
important in selenium nanoparticle assembly. 
Figure 3.11: Sequence alignment of SefA, Is79A3 and AL212 (adapted from Butler et al., 2012) 
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4 Investigating the impact of differentially tagged SefA 
variants on assembly of selenium nanospheres 
4.1 Introduction  
 Having explored the assembly of selenium nanospheres in the 
presence of the rSefA protein, the effect of His-tagging the protein on these 
nanoparticles was investigated. Two His-tagged forms of SefA had been 
previously expressed (Debieux et al., 2011) one with a His-tag only on the N-
terminus (His-SefA) and one with a His-tag on both the N-terminus and the C-
terminus (His-SefA-His).  Both of these forms of SefA were expressed in LB 
Broth and purified by nickel affinity chromatography and gel filtration 
chromatography. These His-tagged forms of SefA were added to the reaction 
between reduced GSH and selenite and the reaction was measured 
spectrometrically, at 400 nm, to monitor the formation of selenium deposits. 
This involved measuring absorbance as a function of time, carrying out 
nanoparticle tracking analysis with an industrial collaborator and, in one 
particular case, measuring the zeta potential.  
 Previous work by Debieux et al. has shown that selenium nanospheres 
produced in vitro in the presence of His-SefA form nanospheres of 300 nm in 
diameter (Debieux et al., 2011). These particles are much larger than both 
those formed in T. selenatis during selenate respiration and those formed in 
vitro in the presence of the rSefA protein. This chapter will be looking to see if 
there are any similarities in the size of the nanospheres as protein 
concentration is increased across the different forms of the SefA protein. As 
the presence of the form of SefA with a His-tag on the N-terminus produces 
larger nanospheres than the rSefA protein, it may be expected that the form 
with a His-tag on both the N-terminus and the C-terminus may produce even 
larger selenium nanoparticles. By investigating how the addition of His-tags 
onto SefA affects the properties of these selenium nanospheres, it may be 
possible to begin to hypothesise how the protein interacts with the 
nanoparticles within T. selenatis and actually exports them out of the cell.  
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4.1.1 Specific aims and objectives 
• Express and purify the recombinant His-SefA and His-SefA-His 
proteins. 
• Investigate the effect of His-tagging the SefA protein on selenium 
nanosphere formation via NTA. 
• Investigate how colloidally stable the selenium nanospheres are by 
determining zeta potential. 
• Attempt to crystallise the His-SefA-His protein in order that its structure 
could be determined. 
4.2 The expression and purification of His-SefA and His-SefA-
 His 
 The two protein constructs were over-expressed in E. coli BL21 
CodonPlus (DE3)-RIPL cells. An overnight culture was grown at 37°C with 
agitation containing the glycerol stock for the appropriate bacterial strain, 
antibiotics and LB broth. This culture was then used to inoculate fresh LB 
broth and was then incubated under agitation at 37°C until the optical density 
(OD600nm) was 0.4. Once the optical density had reached 0.4 the culture was 
cooled for 30 minutes before IPTG was added. Further incubation of the 
culture under agitation took place at 20°C. The cells were then extracted by 
centrifugation and resuspended before the cells were broken open by 
sonication and clarified by further centrifugation. Both proteins were then 
purified using nickel affinity chromatography, where the purified protein was 
eluted in 50 mM Tris-HCl, pH 7.0, 0.5 M NaCl, 1 M imidazole. A further 
purification step was necessary so both proteins were also purified by gel 
filtration chromatography where the pure protein was eluted in 50 mM Tris-
HCl, pH 7.5, 100 mM KCl. SDS-PAGE analysis of the proteins purified by both 
nickel affinity chromatography and gel filtration chromatography can be seen 
in figures 3.1, 4.1 and 4.2. The main protein band in both images is shown at 
approximately 95 kDa, which confirms the presence of the SefA protein.  
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Figure 4.1: SDS-PAGE analysis of His-SefA-His purified by nickel affinity chromatography. Lane 1 = Pre-
Stained protein standard. Lanes 2-11 show elutions from nickel affinity chromatography. 
!
Figure 4.2: SDS-PAGE analysis of His-SefA and His-SefA-His purified by gel filtration chromatography. 
Lanes 1,4,6 and 9= Pre-Stained protein standard, Lanes 2 and 3 show His-SefA after gel filtration and 
lanes 7 and 8 show His-SefA-His after gel filtration. 
! 51!
4.3 In vitro formation of selenium nanospheres in the presence 
 of His-tagged SefA 
 The reaction between reduced glutathione and selenite in the presence 
of His-tagged SefA was investigated. Primarily the reaction was undertaken in 
the presence of His-SefA, the form of SefA with a His-tag on the N-terminus, 
and secondly in the presence of His-SefA-His, the form with a His-tag on both 
the N-terminus and the C-terminus of the protein. The reaction was repeated 
with both proteins at the same range of protein concentrations as with the 
native SefA (0.5 µg/ml, 1 µg/ml, 5 µg/ml, 10 µg/ml and 50 µg/ml) and each 
reaction was undertaken in triplicate. The formation of the red selenium 
nanoparticles was measured spectrometrically at 400 nm, a plot of 
absorbance as a function of time across the different protein concentrations 
can be seen in figure 4.3 in the presence of His-SefA and in figure 4.4 in the 
presence of His-SefA-His.  
 
Figure 4.3: The formation of selenium nanospheres produced in the presence of His-SefA was 
measured spectrometrically shown in this plot of time against absorbance. 
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Figure 4.4: The formation of selenium nanospheres produced in the presence of His-SefA-His was 
measured spectrometrically shown in the plot of absorbance against time. 
 Figure 4.3 shows a general decrease in absorbance as the 
concentration of His-SefA increases, whereas the formation of selenium 
nanospheres produced in the presence of His-SefA-His (figure 4.4) shows an 
increase in absorbance with increasing protein concentration. Plots of final 
absorbance against protein concentration can also be seen in figures 4.5 and 
4.6. These further confirm the trends outlined above. An increase in the 
concentration of His-SefA shows a decrease in final absorbance of the 
selenium nanospheres, whereas an increase in the concentration of His-SefA-
His shows an increase in final absorption. The colour intensity of the 
nanoparticles formed in the presence of these His-tagged proteins can be 
seen in figures 4.7 and 4.8. In the presence of both His-SefA and His-SefA-
His the colour intensity of the nanospheres is decreasing with an increase in 
protein concentration. 
! 53!
 
Figure 4.5: A plot of final absorbance for the nanospheres produced in the presence of His-SefA at 
different protein concentrations. This is an average representation. 
 
Figure 4.6: An average representation of final absorbance against protein concentration for those 
particles produced in the presence of His-SefA-His. 
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Figure 4.7: The selenium nanospheres formed in the presence of 0.5 µg/ml, 1 µg/ml, 5µg/ml, 10 µg/ml 
and 50 µg/ml (from left to right) His-SefA. 
 
Figure 4.8: The selenium nanospheres formed in the presence of 0.5 µg/ml, 1 µg/ml, 5µg/ml, 10 µg/ml 
and 50 µg/ml (from left to right) His-SefA-His. 
4.4 Nanoparticle Tracking Analysis to investigate the effect of 
 His-tagging the Selenium Export Factor on the assembly of 
 selenium nanospheres 
 Particle size of the selenium nanoparticles formed in the presence of 
both His-SefA and His-SefA-His was determined via NTA in collaboration with 
NanoSight Ltd. NTA tracks the Brownian motion of the nanospheres on a 
particle-by-particle basis and particle size can be determined using the 
Stokes-Einstein equation. A video of the nanoparticles in suspension is 
produced during the analysis and a still of the nanospheres in the presence of 
5 µg/ml of His-SefA can be seen in figure 4.9 and those in the presence of 5 
µg/ml of His-SefA-His can be seen in figure 4.10.  
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Figure 4.9: A still image of selenium nanoparticles stabilised by 5 µg/ml His-SefA. The dots represent 
selenium nanospheres produced in-vitro in the presence of 5 µg/ml His-SefA, moving due to Brownian 
motion. 
Figure 4.10: A still image of selenium nanoparticles stabilised by 5 µg/ml His-SefA-His. The dots 
represent selenium nanospheres produced in-vitro in the presence of 5 µg/ml His-SefA-His, moving due 
to Brownian motion. 
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 Figures 4.11-4.13 and 4.14-4.16 show the size distributions of the 
nanospheres produced at different concentrations of His-SefA and His-SefA-
His.  
 
Figure 4.11: Particle size distribution of selenium nanospheres produced in the presence of His-SefA in 
reaction 1. 
 
Figure 4.12: Particle size distribution of selenium nanospheres produced in the presence of His-SefA in 
reaction 2. 
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Figure 4.13: Particle size distribution of selenium nanospheres produced in the presence of His-SefA in 
reaction 3. 
 
Figure 4.14: Particle size distribution of selenium nanospheres produced in the presence of His-SefA-
His in reaction 1. 
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Figure 4.15: Particle size distribution of selenium nanospheres produced in the presence of His-SefA-
His in reaction 2. 
 
Figure 4.16: Particle size distribution of selenium nanospheres produced in the presence of His-SefA-
His in reaction 3. 
 Figures 4.11, 4.12 and 4.13 show that as the concentration of His-SefA 
increases, the size distribution of the selenium nanospheres formed 
decreases. At low concentrations of His-SefA, there is a broad distribution of 
particle sizes (75 – 175 nm) whereas at higher concentrations the size 
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distribution of the particles becomes a lot narrower (50 – 100 nm). Figures 
4.14 – 4.16 show the size distribution of the nanoparticles produced in the 
presence of His-SefA-His. No strong trend can be seen here relating size 
distribution to protein concentration. These plots closely relate to figures 4.17 
and 4.18, showing plots of mean particle size against protein concentration for 
the corresponding protein constructs.  
 
Figure 4.17: A plot of mean particle size at different concentrations of His-SefA. 
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Figure 4.18: A plot of mean particle size at different concentrations of His-SefA-His. 
 Figure 4.17 shows mean particle size against the concentration of His-
SefA, as the concentration of His-SefA increases the mean particle size 
decreases. It can be seen that as the protein concentration increases the size 
distribution of the particles decreases. Figure 4.18 shows the same data 
however for selenium nanoparticles produced in the presence of His-SefA-
His. No general trend can be extracted from this plot, increasing the protein 
concentration does not seem to have an obvious effect on particle size or on 
size distribution. 
4.5 Zeta Potential of His-SefA 
 The apparent drift velocity of each particle can be recorded using a 
ZetaSight system. This technology developed by NanoSight Ltd tracks the 
zeta potential of nanospheres on a particle-by-particle basis. This was applied 
to those nanospheres produced in the presence of 50 µg/ml of His-SefA. 
Figure 4.19 shows a plot of zeta potential against particle concentration 
showing the mean zeta potential to be -39.8 mV.  
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Figure 4.19: A plot of zeta potential against particle concentration. 
4.6 Crystallisation Trials for His-SefA-His 
 Crystallisation trials were run for His-SefA-His (see materials and 
methods 2.7) and three crystals grew in 0.1 M CAPS buffer (pH 10.5), 1 M 
NaBr, 40% MPD. The crystals show a rhombus shape and were 1.6 mm in 
size. It was considered unlikely that they were salt crystals as there was no 
salt in the growth conditions. These crystals were frozen and then exposed to 
a high-intensity and finely focussed beam of monochromatic X-ray radiation to 
produce a diffraction pattern relating to the different properties of the crystal. 
The crystals did not diffract and so such a diffraction pattern was not 
produced. To produce crystals that would diffract it would be necessary to 
optimise crystallisation conditions. The diffraction data collected would need 
to be of high resolution; at least 2.5 Å. 
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Figure 4.20: Three crystals produced of the His-SefA-His protein. 
0.5mm 
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4.7 Discussion 
 SDS-PAGE analysis of the expressed and purified His-SefA and His-
SefA-His proteins shows that the double His-tagged form of the protein is 
slightly purer than the mono His-tagged form. There are faint bands apparent 
at a range of lower molecular weights on the gel, which could indicate the 
presence of other smaller proteins or could be slight degradation of the SefA 
proteins. The colour of the selenium particles which are formed as a result of 
the reaction between reduced GSH and selenite can be seen in the presence 
of both His-SefA and His-SefA-His respectively. In the presence of each 
protein it can be seen that an increase in protein concentration results in a 
decrease in the colour intensity of the protein formed, more dramatically so in 
the presence of His-SefA. For both reactions absorbance at 400 nm was 
measured as a function of time, in the presence of His-SefA a general trend 
can be seen in figure 4.3 that absorbance decreases as protein concentration 
increases, further confirmed in figure 4.5 where a decrease in final 
absorbance can be seen as the protein concentration increases. However in 
the presence of the His-SefA-His protein, there is an increase in absorbance 
as protein concentration increases from 0.5 µg/ml to 50 µg/ml. An increase in 
final absorbance with increasing concentration of His-SefA-His confirms this 
trend. 
 NTA tracks the nanospheres on a particle-by-particle basis and allows 
particle size and size distribution to be determined. The plots of particle size 
against particle concentration for those produced in the presence of His-SefA 
can be seen, along with similar plots for those produced in the presence of 
His-SefA-His. For those nanoparticles produced in the presence of the mono 
His-tagged protein, the size distribution of the nanoparticles becomes much 
smaller as the protein concentration increases. At 0.5 µg/ml and 1 µg/ml a 
broad size distribution of the particles can be seen (50 – 200 nm) however at 
50 µg/ml this becomes much more narrow (25 – 150 nm). For those selenium 
particles produced in the presence of His-SefA-His, a similar trend cannot be 
seen. It would appear that changing the concentration of the protein has no 
effect on the size distribution of these particles. Looking at a plot of mean 
particle size against protein concentration, this is further confirmed, as an 
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increase in protein concentration has no effect on the particle size. For the 
selenium nanospheres produced in the presence of His-SefA, the mean 
particle size decreases as protein concentration increases.  
 
Figure 4.21: An overlay of mean particle size plotted against protein concentration for all three protein 
constructs; SefA, His-SefA and His-SefA-His. 
 A plot in figure 4.21 of mean particle size against protein concentration, 
shows an overlay of all three different forms of the SefA protein: rSefA, His-
SefA and His-SefA-His. The formation of selenium nanospheres in the 
presence of the rSefA protein shows an increase in particle size with 
increasing protein concentration. The addition of an N-terminal His-tag onto 
this protein to form His-SefA has the inverse effect and actually shows a 
decrease in particle size with increasing protein concentration. The addition of 
a His-tag to the N and C-termini of SefA shows no effect of changing protein 
concentration on particle size.  
 The difference in trends across the different protein forms confirms that 
the addition and removal of His-tags to the SefA protein does have an effect 
on the properties of the selenium nanospheres formed during the reaction 
between reduced GSH and selenite. Del Pino et al. considered protein 
adsorption onto nanoparticles as ligand binding (Del Pino et al., 2013). Could 
the addition of the His-tag onto the protein, before protein adsorption onto the 
nanoparticle surface, also be considered as ligand binding? The addition of 
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either an N-terminal or a C-terminal His-tag onto the SefA protein could be 
having a similar effect to the addition of a ligand and changing the way in 
which the protein binds around the nanospheres.  
It is possible that the His-tag itself is interacting with the selenium particles 
and this is affecting the way in which they form and their size. Lin and co-
workers investigated the effect of protein adsorption on the size of selenium 
nanoparticles and stated that the amount of protein added to a reaction 
system will indeed affect the size of the nanoparticles which are formed (Lin et 
al., 2005). Butler et al. suggested that the N-terminus of SefA could be an 
influencing factor on the way in which SefA folds and assembles (Butler et al., 
2012). In this chapter the investigation has focused on the formation of 
elemental selenium in the presence of SefA forms in which the N-terminus 
has been blocked by a His-tag. The conservation of this N-terminus could be 
important for the protein to make protein-protein interactions or protein-
nanoparticle interactions.  
 Peptides have been shown to stabilise nanostructures (Monopoli et al., 
2011) and zeta potential analysis of selenium nanospheres produced in the 
presence of 5 µg/ml His-SefA-His showed a zeta potential of -39.8 mV. 
Colloidally stable suspensions have a zeta potential of -30 mV or less, 
destabilised suspensions -15 mV and minimally stable 0 mV (Buchs et al., 
2013) (Malvern Instruments Ltd.). This shows that elemental selenium 
produced in the presence of a protein with two His-tags, one on the N-
terminus and one on the C-terminus, are colloidally stable. Abe and co-
workers conducted a study investigating apo-ferritin protein nanocages with 
palladium (Abe et al., 2010). Here it was found that altering the positions of 
His-residues on the proteins may control the coordination structures of the 
nanocages. Perhaps the His-tagging affects the protein-particle interactions in 
such a way that it in fact enhances particle stability. 
 It was hypothesised that the SefA and selenium may form similar 
interactions to those between BSA and quantum dots (Bucking et al., 2009). 
The SefA protein may coat these selenium nanospheres within T. selenatis to 
export them out of the cell. Modifications to the proteins with His-tagging 
changes the properties of the selenium nanospheres and could therefore be 
having an effect on the way in which they self-assemble. It is possible that the 
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addition of a His-tag to the N-terminus or the C-terminus of the protein 
actually has an effect on how the protein folds and the different structures of 
these protein forms could then be having different effects on the nanosphere 
assembly. It is unfortunate that the crystals of the His-SefA-His protein did not 
diffract as they could have led to discovering the structure of the protein. The 
lack of effect of His-SefA-His on the size of the selenium nanospheres formed 
suggests that it is in fact the conservation of the C-terminus of SefA which is 
important. Perhaps the C-terminus also has an important role in protein-
protein interactions and the overall assembly of the SefA-Se nanocage. 
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5 Concluding comments and future work 
5.1 Concluding comments 
 The work presented here described an investigation of the effect of 
protein adsorption on selenium nanosphere assembly. This involved looking 
at three different forms of the selenium export factor protein SefA isolated 
from T. selenatis (Debieux et al., 2011).  
 Interestingly, very different results regarding the size of nanospheres 
formed have been seen with each different form of the SefA protein. Selenium 
nanospheres were produced as a product of the reaction of reduced 
glutathione and selenite, in the presence of three different forms of SefA. 
Those produced in the presence of rSefA showed an increase in particle size 
with increasing protein concentration. By comparison, the reaction was 
repeated in the presence of the two His-tagged forms of SefA. In the presence 
of His-SefA, the form with a His-tag only on the N-terminus, particle size 
decreased as protein concentration increased, however in the presence of the 
double His-tagged form His-SefA-His, no trend was seen correlating particle 
size and protein concentration. This confirms the hypothesis that His-tagging 
a protein does in fact have an effect on the nanoparticles which are formed. 
The positive correlation between particle size and protein concentration seen 
when produced in the presence of rSefA, alongside an investigation by Butler 
et al., (2012), primarily led to the suggestion that the N-terminus of the SefA 
protein was involved in the nanocage assembly. However the reaction carried 
out in the presence of His-SefA also showed a correlation, although here 
particle size was seen to decrease with increasing protein concentration, even 
though the N-terminus was blocked by a His-tag. It is not yet clear whether 
the N-terminal region is involved in protein-protein interactions, perhaps with 
an as yet unidentified protein partner, and therefore influences particle-protein 
assembly, or if it is the His-tag itself which is interacting with the 
nanoparticles. The lack of correlation between particle size and protein 
concentration when analysing the particles produced in the presence of His-
SefA-His suggests that perhaps it is not solely the N-terminus which is 
important for particle assembly. This form of the protein has both the N-
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terminus and the C-terminus blocked by His-tags. The absence of a trend 
here indicates that the C-terminus of SefA plays an important role in how the 
protein folds and how this protein-nanocage assembles. 
 These selenium nanoparticles produced in vitro are similar to those 
naturally occurring in the selenate respiring bacterium T. selenatis. The form 
of SefA with no His-tags attached was expected to be the most similar to that 
found in the bacterium itself. Therefore it was expected that the selenium 
nanospheres produced in the presence of this protein would be the most 
similar to those produced within the bacterium. The selenium nanospheres 
isolated from T. selenatis were approximately 130 nm in size, nanoparticles of 
130 nm in size were produced in vitro in the presence of 10 µg/ml SefA. This 
suggests that the internal concentration of SefA within T. selenatis, at the 
point of selenium nanosphere formation, could be in the order of 10 µg/ml. 
Although the nanoparticles formed at 10 µg/ml SefA were 130 nm in size, a 
broader range of sizes was seen across the full range of protein 
concentrations (0.5 µg/ml – 50 µg/ml). This indicates there could be another 
influencing factor within T. selenatis, this could be another peptide which is 
interacting with SefA and having an effect on particle formation. 
5.2 Future work 
 To carry on with the work outlined in this study, the isolation of a 
construct of SefA with a His-tag only on the C-terminus (SefA-His) could give 
more information on the need for conservation of the C-terminus of SefA. The 
N-terminus of His-SefA-His could be cleaved to form SefA-His however 
separating a His-tag from the resulting His-tagged protein SefA-His could be a 
problem. A data set including a protein with the C-terminus blocked, but not 
the N-terminus could give an insight into whether the N- or C-termini are 
influential in protein-selenium interactions and the assembly of the nanocage. 
 This work has suggested that there could be another protein in T. 
selenatis which is interacting with SefA and could be influencing the way in 
which these nanospheres are formed within the cell. The possibility of there 
being a partner protein to SefA could affect the way in which SefA interacts 
with the selenium and forms a nanocage around it. Identification of any other 
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interacting proteins within T. selenatis could give further insight as to how the 
selenium nanospheres are exported out of the cell, perhaps SefA is not the 
only influencing factor.  
 Debieux and co-workers obtained electron microscopy images of 
selenium nanospheres produced within T. selenatis at different stages of the 
growth phases (Debieux et al., 2011). It would be beneficial to obtain some 
similar images for the nanoparticles produced in vitro to compare the shape 
as this might indicate how the different proteins are interacting with the 
nanospheres. It would also be advantageous to carry on with crystallisation 
trials for the SefA protein. To obtain the protein’s structure could give a lot 
more information on the potential for interactions between proteins and 
between the protein and the nanospheres. 
! 70!
6 References 
Abe, S., Hikage, T., Watanabe, Y., Kitagawa, S. and Ueno, T. (2010). 
"Mechanism of accumulation and incorporation of organometallic Pd 
complexes into the protein nanocage of apo-ferritin." Inorg Chem 49(15): 
6967-6973. 
Agapakis, C. M., Boyle, P. M. and Silver, P. A. (2012). "Natural strategies for 
the spatial optimization of metabolism in synthetic biology." Nature Chemical 
Biology 8(6): 527-535. 
Almeida, A. J. and Souto E. (2007). "Solid lipid nanoparticles as a drug 
delivery system for peptides and proteins." Advanced Drug Delivery Reviews 
59(6): 478-490. 
Arner, E. S. J. (2012). “History of Selenium Research.” Selenium: Its 
Molecular Biology and Role in Human Health, Third Edition 1-19. 
Baron, M. H., Revault, M., Servagent-Noinville, S., Abadie, J. and 
Quiquampoix, H. (1999). "Chymotrypsin Adsorption on Montmorillonite: 
Enzymatic Activity and Kinetic FTIR Structural Analysis." Journal of Colloid 
and Interface Science 214(2): 319-332. 
Brandes, N., Welzel, P. B., Werner, C. and Kroh, L. W. (2006). "Adsorption-
induced conformational changes of proteins onto ceramic particles: 
Differential scanning calorimetry and FTIR analysis." Journal of Colloid and 
Interface Science 299(1): 56-69. 
Buchs, B., Evangelou, M. W. H., Winkel, L., H., E. and Lenz, M. (2013). 
"Colloidal Properties of Nanoparticular Biogenic Selenium Govern 
Environmental Fate and Bioremediation Effectiveness." Environmental 
Science & Technology 47(5): 2401-2407. 
Buecking, W., Massadeh, S., Merkulov, A., Xu, S. and Nann, T. (2010). 
"Electrophoretic properties of BSA-coated quantum dots." Analytical and 
Bioanalytical Chemistry 396(3): 1087-1094. 
! 71!
Butler, C. S. (2012). The complexity of bacterial selenate respiration: Metals, 
non-metals and minerals. The Biochemist 34(5): 23-27. 
Butler, C. S., Debieux, C., M., Dridge, E., J., Splatt, P. and Wright, M. (2012). 
"Biomineralization of selenium by the selenate-respiring bacterium Thauera 
selenatis." Biochemical Society transactions 40(6): 1239-1243. 
Chang, J.-S., Chang, K., L., Hwang, D., F. and Kong, Z., L. (2007). "In Vitro 
Cytotoxicitiy of Silica Nanoparticles at High Concentrations Strongly Depends 
on the Metabolic Activity Type of the Cell Line." Environmental Science & 
Technology 41(6): 2064-2068. 
Coppage, R., Slocik, J., M., Briggs, B., D., Frenkel, A., I., Heinz, H., Naik, R., 
R. and Knecht, M., R. (2011). "Crystallographic Recognition Controls Peptide 
Binding for Bio-Based Nanomaterials." Journal of the American Chemical 
Society 133(32): 12346-12349. 
Debieux, C. M., Dridge, E., J., Mueller, C., M., Splatt, P., Paszkiewicz, K., 
Knight, I., Florance, H., Love, J., Titbull, R., W., Lewis, R., J., Richardson, D., 
J. and Butler, C., S. (2011). "A bacterial process for selenium nanosphere 
assembly." Proceedings of the National Academy of Sciences of the United 
States of America 108(33): 13480-13485. 
Delepelaire, P. (2004). "Type I secretion in gram-negative bacteria." 
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1694(1–3): 
149-161. 
Dell'orco, D., Lundqvist, M., Cedervall, T. and Linse, S. (2012). "Delivery 
success rate of engineered nanoparticles in the presence of the protein 
corona: a systems-level screening." Nanomedicine : nanotechnology, biology, 
and medicine 8(8). 
DeMoll-Decker, H. and Macy, J. (1993). "The periplasmic nitrite reductase of 
Thauera selenatis may catalyze the reduction of selenite to elemental 
selenium." Archives of Microbiology 160(3): 241-247. 
Derfus, A. M., Chan, W., C., W. and Bhatia, S., N. (2003). "Probing the 
Cytotoxicity of Semiconductor Quantum Dots." Nano Letters 4(1): 11-18. 
! 72!
Dittrich, C., Burckhardt, C., J. and Danuser, G. (2012). "Delivery of membrane 
impermeable cargo into CHO cells by peptide nanoparticles targeted by a 
protein corona." Biomaterials 33(9): 2746-2753.  
Dobias, J., Suvorova, E., I. and Bernier-Latmani, R. (2011). "Role of proteins 
in controlling selenium nanoparticle size." Nanotechnology 22(19). 
Dombu, C. Y. and Betbeder, D. (2013). "Airway delivery of peptides and 
proteins using nanoparticles." Biomaterials 34(2). 
Dridge, E. J., Watts, C., A., Jepson, B., J., Line, K., Santini, J., M., 
Richardson, D., J. and Butler, C., S. (2007). "Investigation of the redox 
centres of periplasmic selenate reductase from Thauera selenatis by EPR 
spectroscopy." Biochem J 408(1): 19-28. 
Dungan, R. S., Yates, S., R. and Frankenberger, W., T., Jr. (2003). 
"Transformations of selenate and selenite by Stenotrophomonas maltophilia 
isolated from a seleniferous agricultural drainage pond sediment." 
Environmental Microbiology 5(4): 287-295. 
Ehrenberg, M. S., Friedman, A., E., Finkelstein, J., N., Oberdorster, G. and 
McGrath, J., L. (2009). "The influence of protein adsorption on nanoparticle 
association with cultured endothelial cells." Biomaterials 30(4): 603-610. 
Emerson, D., Fleming, E., J. and McBeth, J., M. (2010). Iron-Oxidizing 
Bacteria: An Environmental and Genomic Perspective. Annual Review of 
Microbiology, Vol 64, 2010. S. Gottesman and C. S. Harwood. 64: 561-583. 
Fatisson, J., Quevedo, I., R., Wilkinson, K., J. and Tufenkji, N. (2012). 
"Physicochemical characterization of engineered nanoparticles under 
physiological conditions: Effect of culture media components and particle 
surface coating." Colloids and Surfaces B-Biointerfaces 91: 198-204. 
Fletcher, J. M., Harniman, R., L., Barnes, F., R., Boyle, A., L., Collins, A., 
Mantell, J., Sharp, T., H., Antognozzi, M., Booth, P., J., Linden, N., Miles, M., 
J., Sessions, R., B., Verkade, P. and Woolfson, D., N. (2013). "Self-
Assembling Cages from Coiled-Coil Peptide Modules." Science 340(6132): 
595-599. 
! 73!
Ganther, H. E. (1971). "Reduction of selenotrisulfide derivative of glutathione 
to a persulfide analog by glutathione reductase." Biochemistry 10(22): 4089-
4098. 
Gebauer, J. S., Malissek, M., Simon, S., Knauer, S., K., Maskos, M., Stauber, 
R., H., Peukert, W. and Treuel, L. (2012). "Impact of the Nanoparticle–Protein 
Corona on Colloidal Stability and Protein Structure." Langmuir 28(25): 9673-
9679. 
Gerrard, T. L., Telford, J., N. and Williams, H., H. (1974). "Detection of 
selenium deposits in Escherichia-coli by electron microscopy.” Journal of 
Bacteriology 119(3): 1057-1060. 
Ghosh, A., Mohod, A., M., Paknikar, K., M. and Jain, R., K. (2008). "Isolation 
and characterization of selenite- and selenate-tolerant microorganisms from 
selenium-contaminated sites." World Journal of Microbiology and 
Biotechnology 24(8): 1607-1611. 
Hammer, D. A. and Kamat, N. P. (2012). "Towards an artificial cell." FEBS 
Letters 586(18): 2882-2890. 
Hashimoto, H., Yokoyama, S., Asaoka, H., Kusano, Y., Ikeda, Y., Seno, M., 
Takada, J., Fujii, T., Nakanishi, M. and Murakami, R. (2007). "Characteristics 
of hollow microtubes consisting of amorphous iron oxide nanoparticles 
produced by iron oxidizing bacteria, Leptothrix ochracea." Journal of 
Magnetism and Magnetic Materials 310(2): 2405-2407. 
Hashimoto, H., Fujii, T., Kohara, S., Asaoka, H., Kusano, Y., Ikeda, Y., 
Nakanishi, M., Benino, Y., Nanba, T. and Takada, J. (2012). "Amorphous 
structure of iron oxide of bacterial origin." Materials Chemistry and Physics 
137(2): 571-575. 
Hauck, T. S., Ghazani, A., A. and Chan, W., C. (2008). "Assessing the Effect 
of Surface Chemistry on Gold Nanorod Uptake, Toxicity, and Gene 
Expression in Mammalian Cells." Small 4(1): 153-159. 
Heider, J. and Bock, A. (1993). "Selenium metabolism in micro-organisms." 
Advances in Microbial Physiology, Vol 35 35: 71-109. 
! 74!
Hoshino, A., Fujioka, K., Oku, T., Suga, M., Sasaki, Y., F., Ohta, T., 
Yasuhara, M., Suzuki, K. and Yamamoto, K. (2004). "Physicochemical 
Properties and Cellular Toxicity of Nanocrystal Quantum Dots Depend on 
Their Surface Modification." Nano Letters 4(11): 2163-2169. 
Hu, W., Peng, C., Lv, M., Li, X., Zhang, Y., Chen, N., Fan, C. and Huang, Q. 
(2011). "Protein Corona-Mediated Mitigation of Cytotoxicity of Graphene 
Oxide." ACS Nano 5(5): 3693-3700. 
Ike, M., Takahashi, K., Fujita, T., Kashiwa, M. and Fujita, M. (2000). "Selenate 
reduction by bacteria isolated from aquatic environment free from selenium 
contamination." Water Research 34(11): 3019-3025. 
Illum, L. (2007). "Nanoparticulate systems for nasal delivery of drugs: A real 
improvement over simple systems?" Journal of Pharmaceutical Sciences 
96(3): 473-483. 
Jeong, Y.-K., Sohn, Y. and Kang, J., G. (2014). "Synthesis and 
characterization of Eu(III)-incorporated silica nanoparticles for application to 
UV-LED." Journal of Colloid and Interface Science 423(0): 41-47. 
Johnson, J. A., Saboungi, M-L., Thiyagarajan, P., Csencsits, R. and Meisel, 
D. (1998). "Selenium Nanoparticles: A Small-Angle Neutron Scattering 
Study." The Journal of Physical Chemistry B 103(1): 59-63. 
Kessi, J. and Hanselmann, K. W. (2004). "Similarities between the abiotic 
reduction of selenite with glutathione and the dissimilatory reaction mediated 
by Rhodospirillum rubrum and Escherichia coli." Journal of Biological 
Chemistry 279(49): 50662-50669. 
Klein, J. (2007). "Probing the interactions of proteins and nanoparticles." 
Proceedings of the National Academy of Sciences 104(7): 2029-2030. 
Krafft, T., Bowen, A., Theis, F. and Macy, J., M. (2000). "Cloning and 
sequencing of the genes encoding the periplasmic-cytochrome B-containing 
selenate reductase of Thauera selenatis." DNA sequence : the journal of DNA 
sequencing and mapping 10(6): 365-377. 
! 75!
Kreuter, J., Nanoparticles as drug delivery systems, in: H.S. Nalwa (Ed.), 
Encyclopedia of Nanoscience and Nanotechnology, vol. 7, American Scientific 
Publishers, Stevenson Ranch, U.S.A., 2004, pp. 161–180.  
Kurakhmaeva, K. B., Djindjikhashvili, I., A., Petrov, V., E., Balabanyan, V., U., 
Voronina, T., A., Trofimov, S., S., Kreuter, J., Gelperina, S., Begley, D. and 
Alyautdin, R., N. (2009). "Brain targeting of nerve growth factor using 
poly(butyl cyanoacrylate) nanoparticles." J Drug Target 17(8): 564-574. 
Lee, J.-H., Han, J., Choi, H. and Hur, H., G. (2007). "Effects of temperature 
and dissolved oxygen on Se(IV) removal and Se(0) precipitation by 
Shewanella sp. HN-41." Chemosphere 68(10): 1898-1905. 
Lin, Z.-H. and Wang, C. R. (2005). "Evidence on the size-dependent 
absorption spectral evolution of selenium nanoparticles." Materials Chemistry 
and Physics 92(2–3): 591-594. 
Lloyd, J. R. (2003). "Microbial reduction of metals and radionuclides." FEMS 
Microbiology Reviews 27(2–3): 411-425. 
Losi, M. E. and Frankenberger, W. T. (1997). "Reduction of selenium 
oxyanions by Enterobacter cloacae SLD1a-1: Isolation and growth of the 
bacterium and its expulsion of selenium particles." Applied and Environmental 
Microbiology 63(8): 3079-3084. 
Lowe, E. C., Watts, C., A., Richardson, D., G., Santini, J., M., Singleton, I. and 
Butler, C., S. (2006). "The bioenergetics of selenate respiration in Thauera 
selenatis." Biochimica Et Biophysica Acta-Bioenergetics: 203-203. 
Lowe, E. C., Bydder, S., Hartshorne, R., S., Tape, H., L., Dridge, E., J., 
Debieux, C., M., Paszkiewicz, K., Singleton, I., Lewis, R., J., Santini, J., M., 
Richardson, D., J. and Butler, C., S. (2010). "Quinol-cytochrome c 
Oxidoreductase and Cytochrome c4 Mediate Electron Transfer during 
Selenate Respiration in Thauera selenatis." Journal of Biological Chemistry 
285(24): 18433-18442. 
Lynch, I., Dawson, K., A. and Linse, S. (2006). "Detecting Cryptic Epitopes 
Created by Nanoparticles." Sci. STKE 2006(327): pe14-. 
! 76!
Macy, J. M., Michel, T., A. and Kirsch, D., G. (1989). "Selenate reduction by a 
Pseudomonas species: a new mode of anaerobic respiration." FEMS 
microbiology letters 52(1-2): 195-198. 
Macy, J. M., Rech, S., Auling, G., Dorsch, M., Stackebrandt, E. and Sly, L., I. 
(1993). “Thauera-Selenatis Gen-Nov, Sp-Nov, a member of the beta-subclass 
of proteobacteria with a novel type of anaerobic respiration.” International 
Journal of Systematic Bacteriology 43(1): 135-142. 
Malvern Instruments Ltd.: Worcester, UK, 2004; ZetaSizer Nano Series User 
Manual Version 2.1; 
http://nbct.cornell.edu/facilities/downloads/Zetasizer%20Manual.pdf 
Millington, K. R., Osmond, M., J. and McCall, M., J. (2014). "Detecting free 
radicals in sunscreens exposed to UVA radiation using chemiluminescence." 
Journal of Photochemistry and Photobiology B: Biology 133(0): 27-38. 
Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli 
Bombelli, F. and Dawson, K., A. (2011). "Physical-Chemical Aspects of 
Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of 
Nanoparticles." Journal of the American Chemical Society 133(8): 2525-2534. 
Narasingarao, P. and Häggblom, M. M. (2007). "Identification of Anaerobic 
Selenate-Respiring Bacteria from Aquatic Sediments." Applied and 
Environmental Microbiology 73(11): 3519-3527. 
Nel, A. E., Madler, L., Velegol, D., Xia, T., Hoek, E., M., V., Somasundaran, 
P., Klaessig, F., Castranova, V. and Thompson, M. (2009). "Understanding 
biophysicochemical interactions at the nano-bio interface." Nature Materials 
8(7): 543-557. 
Nemmar, A., Hoet, P., H., Vanquickenborne, B., Dinsdale, D., Thomeer, M., 
Hoylaerts, M., F., Vanbilloen, H., Mortelmans, L. and Nemery, B. (2002). 
"Passage of inhaled particles into the blood circulation in humans." Circulation 
105(4): 411-414. 
Ogasawara, Y., Lacourciere, G. and Stadtman, G., C. (2001). "Formation of a 
selenium-substituted rhodanese by reaction with selenite and glutathione: 
! 77!
Possible role of a protein perselenide in a selenium delivery system." 
Proceedings of the National Academy of Sciences of the United States of 
America 98(17): 9494-9498. 
Oremland, R. S., Herbel, M., J., Switzer Blum, J., Langley, S., Beveridge, T., 
J., Ajayan, P., M., Sutto, T., Ellis, A., V. and Curran, S. (2004). "Structural and 
spectral features of selenium nanospheres produced by se-respiring 
bacteria." Applied and Environmental Microbiology 70(1): 52-60. 
Painter, E. P. (1941). "The chemistry and toxicity of selenium compounds, 
with special reference to the selenium problem." Chemical Reviews 28(2): 
179-213. 
Pino, P. d., Pelaz, B., Zhang, Q., Maffre, P., Ulrich Nienhaus, G. and Parak, 
W., J. (2014). "Protein corona formation around nanoparticles - from the past 
to the future." Materials Horizons 1(3): 301-313. 
Prakash, N. T., Sharma, N., Prakash, R., Raina, K., K., Fellowes, J., Pearce, 
C., I., Lloyd, J., R. and Pattrick, R., A., D. (2009). "Aerobic microbial 
manufacture of nanoscale selenium: exploiting nature’s bio-
nanomineralization potential." Biotechnology Letters 31(12): 1857-1862. 
Prapainop, K., Witter, D., P. and Wentworth, P., Jr. (2012). "A Chemical 
Approach for Cell-Specific Targeting of Nanomaterials: Small-Molecule-
Initiated Misfolding of Nanoparticle Corona Proteins." Journal of the American 
Chemical Society 134(9): 4100-4103. 
Prieur, E., Betbeder, D., Niedergang, F., Major, M., Alcover, A., Davignon, J., 
L. and Davrinche, C. (1996). "Combination of human cytomegalovirus 
recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: 
protection from proteolysis and potentiation of presentation to CD4+ T-cell 
clones in vitro." Vaccine 14(6): 511-520. 
Richardson, D. J. (2000). "Bacterial respiration: a flexible process for a 
changing environment." Microbiology-Uk 146: 551-571. 
! 78!
Saiki, M. and Lowe, T. P. (1987). "Selenium in aquatic organisms from 
subsurface agricultural drainage water, San Joaquin Valley, California." 
Archives of Environmental Contamination and Toxicology 16(6): 657-670. 
Sander, C. S., Chang, H., Salzmann, S., Muller, C., S., Ekanayake-
Mudiyanselage, S., Elsner, P. and Thiele, J., J. (2002). "Photoaging is 
associated with protein oxidation in human skin in vivo." Journal of 
Investigative Dermatology 118(4): 618-625. 
Saptarshi, S., R., Duschl, A. and Lopata, A., L. (2013). "Interaction of 
nanoparticles with proteins: relation to bio-reactivity of the nanoparticle." 
Journal of Nanobiotechnology 11(1): 26. 
Schroder, I., Rech, S., Krafft, T. and Macy, J., M. (1997). "Purification and 
characterization of the selenate reductase from Thauera selenatis." Journal of 
Biological Chemistry 272(38): 23765-23768. 
Soon-Bark, K. and Ken Won, L. (2004). Aerosol Nanoparticles. Dekker 
Encyclopedia of Nanoscience and Nanotechnology - Six Volume Set (Print 
Version), CRC Press. 
Spring, S. (2006). The Genera Leptothrix and Sphaerotilus. The Prokaryotes. 
M. Dworkin, S. Falkow, E. Rosenberg, K.-H. Schleifer and E. Stackebrandt, 
Springer New York: 758-777. 
Suwa, Y., Sumino, T. and Noto, K. (1997). "Phylogenetic relationships of 
activated sludge isolates of ammonia oxidizers with different sensitivities to 
ammonium sulfate." The Journal of General and Applied Microbiology 43(6): 
373-379. 
Takada, J.; Fujii, T.; Nakanishi, M. Japan patent Tokkai JP 2008−177061 
(2008). The potential as a cathode material was publicized in the form of 
patent.  
Tan, M. L., Choong, P., F. and Dass, C., R. (2010). "Recent developments in 
liposomes, microparticles and nanoparticles for protein and peptide drug 
delivery." Peptides 31(1): 184-193. 
! 79!
Tanaka, S., Kerfeld, C., A., Sawaya, M., R., Cai, F., Heinhorst, S., Cannon, 
G., C. and Yeates, T., O. (2008). "Atomic-level models of the bacterial 
carboxysome shell." Science 319(5866): 1083-1086. 
Tomei, F. A., Barton, L., L., Lemanski, C., L., Zocco, T., G., Fink, N., H. and 
Sillerud, L., O. (1995). "Transformation of selenate and selenite to elemental 
selenium by Desulfovibrio-desulfuricans.” Journal of Industrial Microbiology 
14(3-4): 329-336. 
Treuel, L., Brandholt, S., Maffre, P., Wiegele, S., Shang, L. and Ulrich 
Nienhaus, G. (2013). "Impact of Protein Modification on the Protein Corona on 
Nanoparticles and Nanoparticle–Cell Interactions." ACS Nano 8(1): 503-513. 
Uchida, M., Klem, M., T., Allen, M., Suci, P., Flenniken, M., Gillitzer, E., 
Varpness, Z., Liepold, L., O., Young, M. and Douglas, T. (2007). "Biological 
containers: Protein cages as multifunctional nanoplatforms." Advanced 
Materials 19(8): 1025-1042. 
Wohlfart, S., Gelperina, S. and Kreuter, J. (2012). "Transport of drugs across 
the blood-brain barrier by nanoparticles." J Control Release 161(2): 264-273. 
Wolfram, J., Yang, Y., Shen, J., Moten, A., Chen, C., Shen, H., Ferrari, M. and 
Zhao, Y. (2014). “The nano-plasma interface: Implications of the protein 
corona.” Colloids and Surfaces B: Biointerfaces 
http://dx.doi.org/10.1016/j.colsurfb.2014.02.035 
Yang, F., Tang, Q., Zhong, X., Bai, Y., Chen, T., Zhang, Y., Li, Y. and Zheng, 
W. (2012). "Surface decoration by Spirulina polysaccharide enhances the 
cellular uptake and anticancer efficacy of selenium nanoparticles." 
International Journal of Nanomedicine 7: 835-844. 
Zhang J.S., P.R.O.C. Patent 97107038.5, June 17, 1998 
Zhang, L., Li, D. and Gao, P. (2012). "Expulsion of selenium/protein 
nanoparticles through vesicle-like structures by Saccharomyces cerevisiae 
under microaerophilic environment." World journal of microbiology & 
biotechnology 28(12).  
! 80!
Zhang S.Y., P.R.O.C. Patent 02138643.9, May 7, 2003. 
 
 
